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ABSTRACT 
TITLE - A study to assess effectiveness of apitherapy in reducing oral 
mucositis among head and neck cancer patients undergoing radiation 
therapy at Rajiv Gandhi Government General Hospital, Chennai. 
Oral mucositis is the painful inflammation and ulceration of the oral 
mucosa, usually as an adverse effect of radiation therapy. It is a major health 
problem that alters the quality of life and nutritional status of the patients with 
head and neck cancer undergoing radiation therapy.  
Need for the study: As a complementary alternative therapy for oral 
mucositis, honey has the anti bacterial property and antioxidant property to 
improve the anatomical and functional abilities. So the investigator felt that it 
comes within the scope of nursing and wanted to conduct the study to assess 
the effectiveness of this intervention.  
Objectives  
 To assess for oral mucositis among patients with head and neck cancer 
undergoing radiation therapy. 
 To assess the effectiveness of apitherapy for the patients with head and 
neck cancer of experimental group. 
  To compare the pre test and post test level of oral mucositis among head 
and neck cancer patients in experimental group and control group. 
  To find the association between post test level of oral mucositis among 
head and neck cancer patients with selected demographic variables. 
Methodology: Research approach-quantitative approach, Research design ± 
experimental design, Sampling technique ± simple random sampling (lottery 
method), Research setting - outpatient department of radiation therapy at Rajiv 
Gandhi Government General Hospital, Chennai, Study population ± head and 
neck cancer patients undergoing 2nd phase radiation therapy, Tool- 
demographical data and clinical variables, National Cancer Institute-Cancer 
Toxicity Criteria (NCI-CTC) scale. 
Data collection procedure: After obtaining formal permission from 
concerned Head of Department and consent from patients study procedure was 
started. Pre assessment was done and 60 samples were selected. Among 60 
patients 30 were assigned to experimental group & 30 control group. 
Experimental group patients were given 20 ml of pure honey 15 min before and 
15 min after radiation therapy to swish for 5 minutes and then swallow it. 
Simultaneously, routine care given for control group. The procedure continued 
for 14 days. Then both group patients were evaluated at the end of 3rd phase 
(after 14 days) with NCI-CTC scale.  
Data analysis: The data were analysed with descriptive statistics (frequency 
and percentage) and inferential statistics (chi square). 
Study results: The study revealed the pre test and post test effectiveness, 
considering experimental group in ulceration F2=16.16 (p=0.001), Erythema 
F2=28.17 (p=0.001), Pain F2=29.39 (p=0.001) and ability to swallow 
F2=15.67 (p=0.001), which were statistically significant.  
In control group, the pre test and post test effectiveness was assessed 
which shows ulceration F2=1.51 (p=0.67), erythema F2=1.50 (p=0.68), pain 
F2=5.22 (p=0.16) and ability to swallow F2=1.21 (p=0.52) were statistically 
not significant.  
Summary of results: The findings of the study shows that there is significant 
reduction in the oral mucositis after apitherapy among head and neck cancer 
patients undergoing radiation therapy in experimental group has been proved. 
Conclusion: Antibacterial property and antioxidants in honey significantly 
reduces oral mucositis. So, in our Nursing practices the nurses can incorporate 
apitherapy as a part of nursing intervention for the patients receiving radiation 
therapy and chemotherapy in reducing oral mucositis. 
 
Key words: effectiveness, apitherapy, oral mucositis 
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CHAPTER I 
INTRODUCTION 
³$SRVLWLYHDWWLWXGHPD\not solve all your problems, but it will annoy 
HQRXJKSHRSOHWRPDNHLWZRUWKHIIRUW´ 
- Herm Albright 
The concept of perfect positive health cannot become a reality because 
man will never be so perfectly adapted to his environment that his life will not 
involve struggles; failures and sufferings. Positive health will therefore, 
always remain mirages, because everything in our life is subject to change. 
Health in this context has been described as a potentiality - the ability of an 
individual to modify him or itself continually in the face of changing 
conditions of life. 
Decades before, Hippocrates said that cancer as a disease has existed 
all alones with man, Susruta who is the father of surgery explained that cancer 
as a tumour which would ulcerate and would not cure and sow its seeds in 
other parts of the body. Twenty-five centuries ago, cancer was called as 
Karakinos because the swollen blood vessels going and coming from the 
tumour mass. 
Cancer is a disease process that begins when an abnormal cell is 
transformed by the genetic mutation of the cellular DNA. This abnormal cell 
forms a clone and begins to proliferate abnormally, ignoring growth 
regulating signals in environment surrounding the cell. Cancer can occur in 
all persons irrespective of age, sex, socio economic status culture and 
geographical area. Different forms of cancer strikes special age, ethnic gender 
groups which varying frequently and severity. 
Cancer is one of the 2nd largest killer diseases next to the heart disease. 
It is a major health problem that occurs in people of all ethnicities. Cancer 
incidence is highest in men than women. 
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There are over 20 million people living with cancer in the world today. 
The estimate number of cases each year is expected to increase from 2 million 
in 2000 to 15 million in 2020. The number of cancer deaths annually will 
increase from about 6 million to l0 million. Cancer has now become the third 
leading cause of deaths in Asian countries. In India, there are approximately 
2.2 million cases of cancer and around 7, 00,000 new cases are being detected 
each year. Among Indian women cancer in the breast account for nearly 60 
percent of all cancers. Several studies reported that head and neck cancer is 
proportionately on the increase in a metropolitan area of India. 
Interest in complementary alternative medicine has grown dramatically 
over the past several years. According to survey results 80% of patients 
repeated using some type of complementary alternative medicine, in that 54% 
took herbal products and 30 % used relaxation techniques. 
Apitherapy is a type of complementary and alternative therapy which 
helps to reduce the degree of oral mucositis as a complication of radiation 
therapy. Apitherapy or bee therapy , is the product of the common honey bee 
for therapeutic purposes, which  involves the medicinal use of bee stings the 
venom  and it has a strong anti ± inflammatory and pain relieve effect, soften 
VFDU WLVVXHDQG  WRERRVW WKHERG\¶V LPPXQH V\VWHP7KHUHE\V\PSWRPVRI
oral mucositis being reduced. 
The goal of cancer treatment to cure, control and palliation are 
achieved through the use of four treatment modalities include surgery, 
radiation therapy, chemo therapy and biologic therapy. Among these, surgery 
and radiation therapy have remained the most commonly used treatment 
modalities. 
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1.1. Need for study 
Cancer is the leading cause of death around the world. According to 
WHO estimation, that 84 million deaths have taken place due to cancer 
between 2005 and 2015 without intervention. Low income and medium income 
countries are harder hit by cancer than the high resource countries. It is 
HVVHQWLDO WR DGGUHVV WKH ZRUOG¶V JURZLQJ FDQFHU EXUGHQ DQG WR ZRUN RQ
effective control measures. 
'LVWULFWV LQ WKH FHQWUDO VRXWKQRUWKHDVW ,QGLDKDYH WKHZRUOG¶VKLJKHVW
incidence of cancer associated with tobacco in India.  Aizawl district in the 
QRUWKHDVWVWDWHRI0L]RUDPKDVWKHZRUOG¶VKLJKHVWLQFLGHQFHRIORZHUSKDU\Q[
cancer and tongue cancer in men and also highest incidence in stomach cancer. 
Madhya Pradesh has the highest incidence of mouth ulcer in the world. Rate of 
stomach cancer were high among men in Bangalore, Chennai and also detected 
highest incidence in women in coastal district, Kerala, Karnataka and Goa. 
Lung cancer is the most common cancer in men in Calcutta, Mumbai and New 
Delhi.  
From the experience of working in various health settings, the 
investigator observed that almost all the patients undergoing radiation therapy 
experience complications and side effects like alopecia, oral mucositis, nausea, 
vomiting and anorexia. Out of these complications oral mucositis is painful and 
prevents the patient to take adequate nutrition.  
The investigator felt that there is a need to do some intervention to 
reduce the oral mucositis among head and neck cancer patients undergoing 
radiation therapy.  After reviewing related literatures the investigator came to 
know the Apitherapy has good effect in reducing oral mucositis among head 
and neck cancer patients undergoing radiation therapy. So the researcher 
planned to conduct a study by using Apitherapy in reducing the oral mucositis 
among head and neck cancer patients undergoing radiation therapy.  
  
4 
 
1.1. Statement of the problem 
³$study to evaluate the effectiveness of apitherapy in reducing oral 
mucositis among head and neck cancer patients undergoing radiation 
therapy at Rajiv Gandhi Government General Hospital, Chennai´ 
1.2. Objectives of the study 
 To assess for oral mucositis among patients with head and neck cancer 
undergoing radiation therapy. 
 To assess the effectiveness of apitherapy for the patients with head and 
neck cancer of experimental group. 
 To compare the pre test and post test level of oral mucositis among head 
and neck cancer patients in experimental group and control group. 
  To find the association between post test level of oral mucositis among 
head and neck cancer patients with selected demographic variables. 
1.2. Operational definition 
 effectiveness : The extent to which the apitherapy has brought about the 
significant difference between experimental group and control group 
which is measured in terms of statistical measurement.  
 apitherapy:  Apitherapy is the use of products of the common honey bee 
for therapeutic purposes. In this study it refers to administration of 20 ml 
of pure honey before and after 15 minutes of radiation and 6 hours after 
the radiation to the experimental group to reduce the inflammation, pain, 
VRIWHQWKHVFDUWLVVXHDQGERRVWWKHERG\¶VLPPXQHV\VWHP 
 oral mucositis: Oral mucositis is the painful inflammation and ulceration 
of the oral mucosa, usually as an adverse effect of radiation therapy. 
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 cancer: Cancer is the diseases of a cell. It is characterized by a shift in 
the control mechanisms of the cell which govern cell survival; 
proliferation and differentiation such cell multiply excessively and form 
local tumors that can invade adjacent normal structures.         
 patient:  Refers to head and neck cancer patients undergoing 2nd phase 
radiation therapy. 
 radiation therapy: Radiation therapy is the emission and distribution of 
energy through space or material medium. The energy produced by 
radiation, when absorbed into tissue, produces ionizing and excitation. 
This local energy is sufficient to break chemical bonds in DNA, which 
leads to biological effect. 
1.3. Assumption 
x Antibacterial property and antioxidants in honey may reduce oral 
mucositis. 
1.4. Hypothesis 
H1 - There is reduction in oral mucositis after apitherapy among head and 
neck cancer patients undergoing radiation therapy in experimental group.  
1.5. Delimitations  
x The study was conducted to time period of four weeks 
x Study findings can be generalised and performed at Rajiv Gandhi 
Government General  Hospital, Chennai 
x Subjects selected with age group of 25 ± 65 years with oral mucositis 
induced by radiation therapy for head and neck cancer. 
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CHAPTER - II 
REVIEW OF LITERATURE 
Oral mucositis is actually a widespread and possible serious 
consequence of high-dose chemotherapy and radiotherapy treatments 
frequently becoming evident as erythematic and aching ulcerative abrasions of 
the mouth and even the throat.  
The literature gathered from through review is depicted under the 
following headings. 
2.1 Literature related to radiation induced oral mucositis among head and neck 
cancer patients undergoing radiation therapy 
2.2 Literature related to complementary and alternative therapy in reducing 
degree of oral mucositis among head and neck cancer patients undergoing 
radiation therapy 
2.3 Literature related to Apitherapy in reducing oral mucositis among head and 
neck cancer patients undergoing radiation therapy 
2.1. Literature related to radiation induced oral mucositis for head 
and neck cancer patients undergoing radiation therapy 
Alison., M. et al (2002) conducted a perspective study on complication 
of radiation therapy for head and neck cancers, by personal interviews were 
conducted with 33 individuals who had received radiation therapy for head and 
neck cancers. Overall, lethargy and weakness, dry mouth, mouth sores and 
pain, taste changes and sore throat were the most frequently reported side 
effects. The single most debilitating side effect was oropharyngeal mucositis 
that was characterized by patients as sore throat and mouth sores and pain both 
negatively affected the patients to experience significant weight loss. As a 
conclusion trends toward more aggressive management for oropharyngeal 
mucositis occurring in patients receiving radiotherapy.  
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Shanthi Appavu (2006) conducted a descriptive study on Nurses roles 
in the management and prevention of oral complications related to cancer 
treatment at International cancer centre, Neyyoor. The findings revealed that 
the majority of staff (67.5%) reported they give more important to oral 
mucositis. More than one third of the nurses had also reported that they inspect 
for local infection (37.5%), Xerostomia (37.5%), functional disabilities 
(15.0%), taste alteration (20.0%) and abnormal dental development (10.0%). 
As a conclusion there is a great need to educate not only nurses but relatives 
and the patients to adopt certain preventive strategies to reduce the prevalence 
of oral complications related to cancer treatment. 
Rubina C. M., et al (2007) conducted an evaluative study of some oral 
post radiotherapy sequelae in patients treated for head and neck tumors. One 
hundred patients (24 women, 76 men) ranging in age from 30 to 83 years 
(mean 59.2 years) were examined. The evaluation protocol included anamnesis, 
intraoral and extraoral examination, measurement of stimulated salivary flow 
and salivary PH symptoms reported by the patients included dry mouth (68%), 
dysphagia (38%) and dysgeusia (30%). The mean salivary PH was 6.97 (± 
o.714) stimulated salivary flow increased with increasing post radiotherapy 
time (P< 0.05). As a conclusion the prevalence of mucositis was associated 
with higher radiation doses (P< 0.05) and the prevalence of atrophic 
candiadiasis was related to a longer post treatment period (P < 0.05) 
Goyal. M et al (2009) conducted prospective study on oral mucositis in 
morning vs evening irradiated patients. The purpose of the study to evaluate 
prospectively the severity of acute oral mucositis in head and neck carcinoma 
patients irradiated in the morning (08.00 ± 11.00h) versus late 
afternoon/evening (15.00±18.00h). The results shows the grades of mucositis 
were marginally higher in the evening irradiated group than in the morning 
irradiated group 38%versus26% (P=0.08). In conclusion the observed 
incidence may be because of the existence of circadian rhythm in the cell cycle 
of normal mucosa.  
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Murphy., B. A. et al (2009) conducted a prospective, longitudinal, 
multicenter, non interventional study on mucositis related morbidity and 
resource utilization in head and neck cancer patients receiving radiation therapy 
with or without chemotherapy. The objective of this study was to estimate 
health care resource utilization in head and neck cancer (HNC) patients. Over 
the course of the treatment, 57 (76%) patients reported severe mouth and throat 
soreness during the course of therapy despite the use of opoid analgesics in 64 
(85%) of the patients. As a conclusion this study demonstrates that mucositis 
related pain and functional impairment is associated with increased use of 
costly health resources. Effective treatments to reduce the pain and functional 
impairment of oral mucositis are needed in this patient population. 
2.2. Literature related to complementary and alternative therapy in 
reducing degree of oral mucositis among head and neck cancer 
patients undergoing radiation therapy 
Nikolettti., S et al (2005) conducted a randomized, controlled, crossover 
trial study to evaluate the effect on mucositis and to determine SDWLHQWV¶ 
perception of the two forms of oral cryotherapy in the outpatient department in 
Perth, Western Australia. The two main forms of oral cryotherapy were taste of 
flavored ice and lain ice. Side effects such as nausea, sensitivity and headache 
were reported more frequently for flavored ice (n=11), compared with plain ice 
(n=5), and standard care (n=1). As a conclusion both forms oral cryotherapy 
were effective in reducing the severity of oral mucositis and were more 
effective than standard care alone. Flavored ice was associated with the highest 
frequency of side effects 
Hong., J.P. et al (2005) conducted a experimental study to evaluate the 
wound healing effect of human recombinant epidermal growth factor in 
treatment of radiation induced severe oral mucositis in patients with head and 
neck malignancies at Asan Medical Center. Patients at who had undergone 
definitive RT of the head and neck region with or without combined 
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chemotherapy and who had developed severe oral mucositis were treated with 
topical rhEGF twice daily for 7 days. The evaluation of response with regard to 
oral mucositis was performed 1 week later. All patients showed improvements 
in their oral mucositis after topical treatment with rhEGF in that the Radiation 
Therapy Group grade was significantly decreases(p=0.0000). As a conclusion 
this findings suggests that rhEGF is effective and safe for the treatment of 
radiation-induced mucositis. 
Debra., L. (2006) conducted a randomized controlled trial study (RCTS)  
on a systemic review of evaluating alternative and complementary therapies for 
cancer related pain. Seven trials reported significant benefit for the following 
CAM therapies, acupuncture (n=1), support groups (n=2), hypnosis (n=1), 
relaxation/imagery (n=2), herbal supplement (n=1). Four studies reported to 
benefit to CAM interventions, music (n=2), massage (n=2) in reducing cancer 
pain compared with a control arm. As a conclusion, CAM interventions for 
cancer pain with adequate power, duration was effective.  
Alterio., D. et al (2006) conducted a experimental study to assess 
feasibility, pain relief and toxicity tetracaine based oral gel in the treatment of 
radiotherapy (RT) induced oral mucositis. 50 patients treated with RT for head 
and neck cancer with clinical evidence of acute oral mucositis of grade >or=2 
were scheduled to receive the tetracaine gel. A questionnaire evaluating the 
effect of the gel was given to all subjects. The result shows in 38 patients 
(79.2%) a reduction in oral cavity pain was reported. 34 patients (82.9%) 
reported no side effects. 71% of patients had any difficulties in gel application. 
Unpleasant taste of the gel and interference with food taste were noticed in 
5(12%) and 16patients (39%) respectively. As a conclusion tetracaine oral gel 
administration seemed feasible and safe while reducing RT- induced mucositis 
related oral pain in a sizeable proportion of treated head and neck cancer 
patients.  
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Arun Maiya., et al. (2006) conducted a true experimental study on low 
level heliumneon (He-Ne) laser therapy in the prevention and treatment of 
radiation induced mucositis in head and neck cancer patients. The study group 
patients were treated with (He- Ne) laser and control group patients were given 
oral analgesics, local application of anesthetic 0.9% saline and povidine wash 
during the course of radiotherapy. The result shows a significant difference in 
pain and mucositis (p<0.001) between the two groups. As a conclusion the low 
level (He-Ne) laser therapy during radiotherapy treatment was found to be 
effective in preventing and treating the mucositis in head and neck cancer 
patients. 
Chambers., M. S et al (2006) conducted a double blind study to 
evaluate the effect of RK-0202 on the incidence of severe oral mucositis in 
patients being treated with of radiation therapy (RT) for tumors of the head and 
neck. Oral mucositis was assessed twice weekly throughout RT by trained oral 
evaluators. The result shows the higher dose of RK- 0202 (10%) successfully 
attenuated severe oral mucositis. As a conclusion RK-0202 significantly reduce 
the incidence of severe mucositis in subjects treated with radiotherapy for head 
and neck cancer and was not associated with significant adverse events. 
King-IRQJ HW¶DO  conducted a comparative study to assess the 
efficacy of 0.2% chlorhexidine gluconate and 0.15% benzydamine 
hydrochloride oral rinses in alleviating irradiation oropharyngeal mucositis for 
patients with head and neck cancer. 14 subjects were randomly assigned to 
chlorhexidine (n=7) or benzydamine (n=7). In result chlorhexidine arm 4 
subjects (57%) had grade 2, 3 subjects (71%) had grade 2 and 2 subjects (29%) 
had grade 3 mucositis. In benzydamine arm 5 subjects (71%) had grade 2, 2 
subjects (29%) had grade 3 mucositis (p> 0.05). As a conclusion a lessening of 
severity of oral mucositis, pain, dysphagia for patients with head and neck 
cancer receiving benzydamine oral rinse. 
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Madankumar., P.D et al (2008) conducted a comparative study to 
assess the effect of three alcohol free mouthwashes on radiation induced oral 
mucositis in patients with head and neck malignancies.80 patients with head 
and neck malignancies, scheduled to undergo curative radiotherapy were 
randomly assigned to receive one of the three alcohol free test mouthwashes 
(0.12% chlorhexidine, 1% povidone iodine or salt/soda). The patients were 
instructed to rinse their mouth with 10ml of the mouthwash, twice a day, for a 
period of 6 weeks. Mucositis was assessed by using WHO assessment scale. In 
results among 76 patients, patients in the povidone iodine group had 
significantly lower mucositis scores when compared to the control group from 
the first week of radiotherapy. As a conclusion use of alcohol free povidone 
iodine mouthwash can reduce the severity and delay the onset of oral mucositis 
due to antineoplastic radiotherapy.  
Ozlem., et al (2009) conducted a multivariate analysis study to evaluate 
the prevalence of and factors related to the use of complementary and 
alternative medicine among cancer patients undergoing or following 
conventional treatment at the Erciyes University Oncology Hospital in Central 
Anatolia. A total of 268 consecutive cancer patients were enrolled in the study. 
Overall, 43% of the patients were using or had used complementary/alternative 
medicine. Nearly half of the patients using complementary/alternative medicine 
(46.1%) were aiming to fight the disease. Among users, half regarded the 
method used as effective and 54(50.5%) suggested the use of 
complementary/alternative medicine to other patients. As a conclusion use of 
complementary/alternative medicine among cancer patients in this center was 
modestly high, and the most common method was herbal therapy. 
Castro., G. et al (2009) conducted a prospective, randomized, double 
blind study to evaluate the efficacy of LLL (low level laser therapy) to decrease 
and delay severe oral mucositis and its impact on RT interruptions. The result 
shows 73 patients were included, 36 patients received prophylactic LLL mean 
delivered RT dose (Gray) was higher in patients treated with LLL ( 69.3 VS 
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67.8, P=O,O4). As a conclusion LLL therapy was effective in reducing grade 3 
or 4 oral mucositis and in reducing RT interruptions in these head and neck 
cancer patients treated with concurrent radiation therapy which is efficacy and 
tolerance.  
Zanin., J. et al (2010) conducted a study to evaluate quantitatively and 
qualitatively the effect of a 660-nm diode laser in the prevention and treatment 
of human oral mucositis in head and neck cancer patients undergoing radiation 
therapy. 72 patients with head and neck patients divided in to a control group 
(c; n=36) and a laser group (L; n=36). Laser therapy was performed in 
combination with radiotherapy and chemotherapy twice a week using a diode 
laser. Patients in group L usually did not present with oral mucositis ranging 
from level I to III associated with pain. As a conclusion laser therapy was 
effective in preventing and treating oral effects induced by radiotherapy and 
FKHPRWKHUDS\WKXVLPSURYLQJWKHSDWLHQW¶VTXDOLW\RIOLIH 
2.3.  Studies related to Apitherapy in reducing oral mucositis in 
head and neck cancer patients undergoing radiation therapy 
Ahmad Zakaria., et al (2003) conducted a quasi experimental study on 
honey treatment for prevention of oral mucositis and gingivitis. Patients 
consumed 20 ml (one and one- third teaspoon) of pure honey 15 minutes 
before, 15 minutes after and 6 hr post ± treatment. There was significant 
reduction in the symptomatic grade three-four mucositis among honey treated 
patients compared with controls i.e. 20% versus 75% (p < 0.001). In result the 
compliance of the honey treated group of patients was better than control. A 
total of 55% patients treated with topical honey showed no change or a positive 
gain in body weight compared with a positive gain in body weight compared 
with only 25% in the control arm( P = 0.05). As a conclusion honey has 
potential for the treatment of periodontal diseases, mouth ulcers and other 
problems of oral health. 
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 %LVZDO HW µDO    conducted a study on topical application of 
honey in the management of radiation mucositis. The aim of the study was to 
evaluate the effect of pure honey on radiation induced mucositis. In this study 
arm, patients were advised to take 20 ml of pure honey 15 min before, 15 min 
after and 6 h post radiation therapy. The main result of the study was there was 
significant reduction of symptomatic grade ¾ mucositis among honey±treated 
patients compared to controls i,e 20% vs 75% ( p 0.00058 ). The compliance of 
honey treated group of patients was better than controls. As a conclusion 
topical application of natural honey is a simple and cost- effective treatment in 
radiation mucositis.  
Apitherapy News (2008) the aim of the study is to evaluate the effect of 
pure natural honey on radiation induced mucositis. In this randomized single 
blind (examiner blind) clinical trial 40 patients with head and neck cancer 
requiring radiation to the oropharyngeal mucosa were randomly assigned to 
two groups. In the study group patients were instructed to take 20 ml of honey 
15 minutes before and 15 minutes and six hours after radiation. In control 
group patients were instructed to rinse with 20 ml of saline before and after 
radiation. Result shows a significant reduction in mucositis among honey 
received patients compared with controls (p = o.ooo) occurred. As a conclusion 
within the limits of this study the results showed the application of natural 
honey is effective in managing radiation induced mucositis.  
Rashad UM et al (2009) conducted an evaluative study on honey as 
topical prophylaxis against radiochemotherapy induced mucositis in head and 
neck cancer. 40 patients diagnosed with head and neck cancer were entered 
into the trial. Patients were evaluated clinically every week to assess 
development of radiation mucositis. In the results in the treatment group, no 
patients developed grade four mucositis and only 3 patients (15%) developed 
grade three mucositis. In the control group 13 patients (65%) developed grade 
three or four mucositis (p< 0.05). As a conclusion this study shows that 
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prophylactic use of pure natural honey was effective in reducing mucositis 
resulting from radiochemotherapy in patients with head and neck cancer.  
Khanal., et al (2010) conducted a single blind, randomized, controlled 
clinical trial study on effect of topical honey on limitation of radiation-induced 
mucositis. The study was carried out to compare the mucositis limiting 
qualities of honey with lignocaine. The result shows only 1 of 20 patients in the 
honey group developed intolerable oral mucositis compared with lignocaine 
group, indicating that honey is strongly protective (RR=0.067) against the 
development of mucositis. The proportion of patients with intolerable oral 
mucositis was lower in the honey group and this was statistically significant 
(p=0.000). As a conclusion honey applied topically to the oral mucosa of 
patients undergoing radiation therapy appears to provide a distinct benefit by 
limiting the severity of mucositis. 
Gezawy S.M. AL (2013) did a double blind study on honey as topical 
prophylaxis against radiotherapy- induced mucositis in head and neck cancer at 
Assiut University Hospital, Egypt. Enrolled patients were randomized to either 
the treatment group, receiving concomitant chemotherapy and radiotherapy 
plus prior topical application of pure natural honey, or the control group, 
receiving concomitant chemotherapy and radiotherapy without honey. In the 
result in treatment group, no patients developed grade four mucositis and only 
three patients (15%) developed grade three mucositis where as in the control 
group, 13 patients, (65%) developed grade three to four mucositis (p< o.o5). 
Candida colonization was found in 15% of the treatment and 60% of the 
control group, either during or after radiotherapy (p= 0.003). Positive cultures 
for aerobic pathogenic bacteria were observed in 15% percent of the treatment 
group and 65% of the control group, during or after radiotherapy (p=0.007). As 
a conclusion this study shows that prophylactic use of pure honey was effective 
in reducing mucositis resulting from radiotherapy in patients with head and 
neck cancer. 
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Kaur Harinderjeet, et al (2015) conducted an experimental study to 
assess the effectiveness of honey in oral mucositis in Punjab. The findings of 
the study revealed that the mean pre test grade of oral mucositis of 
experimental & control group were 2.5±0.93 & 2.26±0.94 respectively. After 
providing intervention, twice a day for 7 days to experimental group the mean 
post test grade of oral mucositis of experimental was 1 ± 0.98 and in control 
group after no any intervention was 2.53 ± 1.04 respectively. It indicated that, 
there was significant (t cal. 6.0489? t table 1.96 at p? 0.05) difference between 
pre test and post test grade of oral mucositis of cancer patients in the 
experimental group than control group. So, it is concluded that topical 
application of honey is effective for reduction of grade of oral mucositis among 
cancer patients.  
2.2. Conceptual framework 
The conceptual framework for this study was direction from 
:LHGHQEDFK¶VKHOSLQJDUWRIFOLQLFDOQXUVLQJWKHRU\ 
$FFRUGLQJWR(UQHVWLQH:LHGHQEDFK¶V1XUVLQJLVDKHOSLQJVHUYLFHWKDW
is rendered with compassion, skill and understanding to those in need for care, 
counsel and confidence in the area of health. The practice of nursing comprises 
a wide variety of services each directed toward the attainment of one of its 
three components. 
Step I: Identification of a need for help. 
Step II: Ministering the help needed. 
Step III: Validation that the need for help was met. 
Central purpose 
The central purpose is to reduce the degree of oral mucositis among 
head and neck cancer patients undergoing radiation therapy 
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Step I- Identification of a need for help 
The head and neck cancer patients undergoing 2nd phase of radiation 
therapy are selected. The general information which comprises assessment of 
demographic variables for both experimental and control group such as age, 
sex, religion, education, family monthly income, personal habits, family history 
of cancer, duration of illness and duration of treatment. Pre assessment of oral 
mucositis done in both experimental group and control group by NCI-CTC 
scale. 
Step II: Ministering the help needed 
In this step ministering to the patient the nurse may give advice or 
information, make a referral, apply a comfort measures or carry out a 
therapeutic procedures. The nurse will need to identify the cause and if 
necessary make an adjustment in the plan of action.  
Ministering of help needed it has two component. 
  Prescription 
  Realities 
Prescription 
It specifies both the nature of the action that will most likely lead to 
IXOILOOPHQW RI WKH QXUVH¶V FHQWUDO SXUSRVH DQG WKH WKLQNLQJ SURFHVV WKDW
determines it. 
Prescription - apitherapy is the plan of care to achieve the purpose. This 
includes in experimental group oral administration of 20 ml of pure honey 
group before and after 15 minutes radiation treatment advise the patient to 
swish it for 5 minutes then swallow it, and advise the patient to repeat the same 
for in their homes after 6 hours of post radiation for 14 days (from 23rd day to 
36th day). 
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Realities 
Realities of the situation is the one in which the nurse is to provide 
nursing care. Realities consist of all factors -physical, physiological, emotional 
and spiritual that are at play in a situation in which nursing actions occur at any 
JLYHQ PRPHQW :LHGHQEDFK¶V GHILQHV WKH ILYH UHDOLWLHV DV WKH DJHQW WKH
recipient, the goal, the means and the framework. 
Agent: Investigator 
Recipient: Head and neck cancer patients undergoing Radiation therapy. 
Goal: To reduce the degree of oral mucositis among head and neck cancer 
patients undergoing radiation therapy. 
Mean: Apitherapy administration for 14 days in experimental group. 
Frame work: Radiation Outpatient department in Rajiv Gandhi Government 
General Hospital at Chennai. 
Step III: Validation that the need for help was met 
After help has been ministered the nurse validates that the actions were 
indeed helpful. Evidence must come from the patient that the purpose of the 
nursing actions has been fulfilled. 
Validating the need for help was met by means of post assessment for 
both experimental and control group with the NCI-CTC Scale and by 
observational check list to assess the degree of oral mucositis on the 14th day. 
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CHAPTER - III 
RESEARCH METHODOLOGY 
Research methodology involves the description of research approach, 
data collection period, study setting, study population, sample size, sampling 
technique, sample selection criteria, research variables,  tools and method of 
data collection, content validity, ethical consideration, pilot study, reliability 
and analysis to answer a specific research questions or for testing research 
hypothesis. 
3.1. Research approach  
 The quantitative approach was used to evaluate the effectiveness of 
apitherapy in reducing oral mucositis among head and neck cancer patients 
undergoing radiation therapy. 
3.2. Data collection period 
 The study was conducted for the period of four weeks (from 15.07.15 to 
15.08.15) 
3.3. Study setting 
The study was conducted in Outpatient Department of Radiation 
Therapy at Rajiv Gandhi Government General Hospital, Chennai. It is a major 
state-owned hospital situated in Chennai with 3,000 beds and is funded & 
managed by the state government of TamilNadu. Multi specialty services are 
rendered by the hospital. The hospital is treating about 10,000 to 12,000 
outpatients every day. 
The department of Radiation Oncology, Barnard Institute of Radiology 
& Oncology, Madras Medical College was started in 1922. In 1930s, two 
institutions started their radiotherapy work. One was in England and the other 
is our department. Hence ours is the first and oldest premier institute in the 
whole of South East Asia. The Department specializes in providing 
Radiotherapy treatment to all cancers where indicated in the form of Neo-
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adjuvant, Adjuvant, Concurrent & Palliative treatment. In radiation oncology 
department, inpatient bed strength is 231 beds and outpatient census is 150-170 
patients/day. 1n 2015, the inpatient census was 15,956 in which head and neck 
cancer patients was 7,567. 
 
3.4. Study design 
The research design used for this study is experimental design.  
 3.5. Study population 
The target population of the study is head and neck cancer patients 
undergoing 2nd phase of radiation therapy at Rajiv Gandhi Government General 
Hospital, Chennai. 
3.6. Sample size 
Sample size is 60. Among 60 Head and neck cancer patients, 30 were in 
experimental group and 30 were in control group. 
3.7. Sampling criterion  
3.7.1. Inclusion criteria 
 Both female and male patients undergoing radiation therapy in outpatient 
department 
 Head and neck cancer patients with the age group of 25 ± 65yrs 
 Head and neck cancer patients undergoing 2nd phase radiation therapy 
continues for 14 days 
 Head and neck cancer Patients who understand, speak Tamil or English 
 Head and neck cancer patients who are all willing to participate in this 
study. 
 
 
   
  
Random 
assignment 
Experimental 
group 
Post 
test 
Intervention  
Control  
group 
Post 
test 
Pre 
test 
Pre 
test 
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3.7.2. Exclusion criteria 
 Head and neck Cancer patients with Diabetes mellitus 
 Head and neck Cancer patients who are critically ill 
3.8. Sampling technique 
Simple random sampling technique (lottery method) was used to select 
the samples for the study.  
3.9. Research variables  
Independent Variable  
 Apitherapy  
Dependent Variable  
Head and neck cancer Patients with oral mucositis  
3.10. Development and description of the tool 
After an extensive review of literature and discussion with the experts 
the following tools are prepared to collect data.  
3.10.1. Development of the tool 
 The tool is developed after extensive review of literature, internet search 
and discussion with experts and statistician in order to develop guidelines for 
providing apitherapy and duration of apitherapy. An observation checklist for 
assessment of radiation therapy induced oral mucositis based on the National 
Cancer Institute-Cancer Toxicity Criteria (NCI-CTC) was developed. 
 3.10.2. Description of the tool 
The tool consisted of two sections.  
Section-A 
  Demographical and clinical variables of the head and neck cancer 
patients were age, gender, education, family monthly income, religion, personal 
habits, family history of cancer, duration of illness, and duration of treatment. 
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Section-B 
Observational Check list & Scoring Key. It consist of 4 items such as 
1. Ulceration 
2. Erythema 
3. Pain 
4. Ability to swallow 
Each item is categorized as follows, 
Ulceration 
 0 = No Lesion Score 0  = No Lesion    
 1 = <1cm2   Score 1-9  = Mild     
 2 = 1-3cm2  Score 10-18  = Moderate    
 3 = >3cm2  Score 19- 27  = Severe    
Erythema 
 0 = No Lesion Score 0  = No Lesion    
 1 = <1cm2  Score 1-9  = Mild     
 2 = 1-3cm2  Score 10-18  = Moderate    
 3 = >3cm2  Score 19- 27  = Severe    
Pain 
 0 = No Pain    Score - 0 
 1-3 = Mild Pain   Score - 1 
 4-6 = Moderate Pain  Score ± 2  
 5-9 = Severe Pain   Score - 3 
 10 = Worst Possible Pain  Score - 4 
Ability to swallow 
 Ability to swallow foods without pain    -Score 3 
 Ability to swallow with pain   - Score 2 
 Requires intravenous rehydration  - Score 1 
 Require parenteral or enteral nutrition  - Score 0 
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3.10.3. Intervention protocol 
Protocol  Experimental group Control group  
Place Radiation therapy outpatient 
department 
Radiation therapy 
outpatient department 
Dosage 20 ml of honey Routine care  
Duration 5 minutes - 
Frequency Twice - 
Time 
 
15 minutes before radiation 
therapy and 15 minutes after 
radiation therapy. 
- 
 
Administered by  Investigator Self  
 
3.10.4. Content validity 
Content validity was determined by experts from Nursing, Medical and 
Statistician. They suggested certain modifications in tool. After the 
modifications they agreed this tool to evaluate the effectiveness of apitherapy 
in reducing oral mucositis among head and neck cancer patients undergoing 
radiation therapy at Rajiv Gandhi Government General Hospital, Chennai. 
3.11. Ethical consideration 
The study objectives, intervention & data collection procedure was 
approved by the Institutional Ethics Committee, Madras medical College, 
Chennai.  
3.12. Pilot study 
The pilot study was conducted in Rajiv Gandhi Government General 
Hospital, Chennai at radiation oncology outpatient department for period of 3 
days. Among 10 patients, 5 patients were in experimental group and 5 patients 
were in control group. The patients were selected using simple random 
sampling technique. The results showed positive co relation between 
apitherapy and radiation therapy induced oral mucositis. The study was 
practically feasible. Pilot study participants were not included in the main 
study. 
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3.13. Reliability 
After pilot study reliability of the tool was assessed by using Split Half 
method and its correlation coefficient r ±value was 0.83(Ulceration), 0.82 
(Erythema), 0.85(pain), 0.79(Ability to swallow). These correlation coefficients 
are very high and it is good tool to evaluate the effectiveness of Apitherapy in 
Reducing Oral Mucositis among Head and Neck Cancer Patients Undergoing 
Radiation Therapy at Rajiv Gandhi Government General Hospital, Chennai. 
3.14. Data collection procedure 
The investigator obtained permission from the Professor and Head of the 
Department, Department of Radiation Oncology, Rajiv Gandhi Government 
General Hospital, Chennai.  Rapport was established after a brief introduction 
about the study and its purpose. Informed consent was obtained from each 
study participant after giving full information about the study. Anonymity was 
assured to each participant. 
Patients with head and neck cancer who undergo 2nd phase of radiation 
therapy were selected. Collection of demographic data, clinical variables and 
assessment of severity of oral mucositis among study participants using NCI-
CTC scale. Allocation of samples by simple random sampling (lottery method)  
to experimental group and control group. 
Administration of apitherapy to experimental group for 14days (20ml of 
honey to swish for 5 minutes, 15 minutes before and after radiation therapy) 
and routine care to control group. In both group post assessment done at the 
end of the 3rd phase (on 14th day) by using NCI-CTC scale.  
The assessment included examining the oral cavity for, ulceration, 
erythema, pain and ability to swallow. The investigator followed all ethical 
principles for collecting the data. The investigator spent 10 to 15 minutes per 
patient in doing data collection. 
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3.15. Data entry and analysis  
Data were collected and analyzed by using descriptive statistics and 
inferential statistics.  
Descriptive Statistics 
 Frequency and Percentage to describe the demographic data and clinical 
variables of head and neck cancer patients undergoing radiation therapy. 
Inferential statistics 
 Chi ± square test to assess and compare the effectiveness of Apitherapy in 
reducing oral mucositis. 
 Chi ± square test to find the association of degree of oral mucositis among 
head and neck cancer patients undergoing radiation therapy with their 
selected demographic variables. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Research approach ± quantitative research approach 
Research design ± experimental study 
Study setting ± outpatient department of radiation therapy at 
Rajiv Gandhi Government General Hospital, Chennai  
Target population ± head and neck cancer patient undergoing 2nd 
phase of radiation therapy 
Sample size 60 - Allocation of samples by simple random 
sampling technique (Lottery method) 
Experimental group (30) 
Apitherapy  
Post assessment on 14th day for radiation therapy induced 
oral mucositis (by using NCI-CTC tool) 
Control group (30) 
Data analysis and Interpretation with Descriptive and 
Inferential Statistics 
Findings and conclusion  
Figure 3.1. Schematic representation of the research study 
Pre assessment of oral mucositis (by using NCI-CTC tool) 
Routine care 
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CHAPTER-IV 
DATA ANALYSIS AND INTERPRETATION 
³$OOJUHDWWUXWKVDUHVLPSOHLQILQDOanalysis and easily understood: if they 
DUHQRWWKH\DUHQRWJUHDWWUXWKV´ 
-Napoleon Hill 
This chapter explains the statistical analysis performed in the collected 
data. Analysis is a method for rending quantitative, meaningful and providing 
intelligible information. So that the research problem can be studied and tested 
the relationship between the variables. 
Descriptive and inferential statistics were used for analysis of data 
according the objectives of the study. 
ORGANIZATION OF DATA 
Section-A: Distribution of Demographic variables of experimental group and 
control group 
Section-B:  Assess for oral mucositis of the patients with head and neck cancer 
of both experimental and control group. 
Section-C: Assess effectiveness of apitherapy for the patients with head and 
neck cancer of experimental group. 
Section-D: Compare the pre test and post test level of oral mucositis among 
head and neck cancer patients in experimental group and control group. 
Section-E: Association between post test level of oral mucositis among head 
and neck cancer patients with selected demographic variables. 
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Section - A: Distribution of demographical data and clinical variables  
Table 4.1 Distribution of demographical data and clinical variables of head and 
neck cancer patients undergoing radiation therapy  
          N = 60 
S.No
Demographic variables 
& 
Clinical variables 
Experimental 
group 
Control 
group 
Chi 
square 
test f % f % 
1.  Age  
  
  
21 -35 years 3 10.0 4 13.3 F=0.63 
p=0.73 
 
36 -50 years 12 40.0 14 46.7 
51 -65 years 15 50.0 12 40.0 
2. Sex Male 25 83.3 24 80.0 F=0.11 
p=0.73 Female 5 16.7 6 20.0 
3. Religion Hindu 26 86.7 25 83.3 F=0.35 
p=0.84 
 
Christian 3 10.0 3 10.0 
Muslim 1  3.3  2 6.7 
4. Educational 
qualification 
No formal education 5 16.7 5 16.7 F=0.44 
p=0.93 
 
Upto Primary level 17 56.7 19 63.3 
Upto middle school level 7 23.3 5 16.7 
Higher secondary level 1 3.3 1 3.3 
5. Income per 
month 
  
< Rs.5,000 8 26.7 13 43.3 F=1.90 
p=0.38  Rs.5,001 - 10,000 20 66.6 15 50.0 
Rs.10,001 - 15,000 2 6.7 2 6.7 
6. Personal 
habits 
Smoking 3 10.0 5 16.7 F=2.56 
p=0.63  
 
Alcohol 1 3.3 2 6.7 
Smoking and alcohol 17 56.7 11 36.6 
Other tobacco products 4 13.3 5 16.7 
No habit of tobacco or 
alcohol abuse 5 16.7 7 23.3 
7. Family 
history of 
cancer 
Yes 1 3.3 2 6.7 F=0.35 
p=0.55  
No 29 96.7 28 93.3 
8. Duration of 
illness 
0 - 3 months 23 76.6 18 60.0 F=2.27 
p=0.32  
 
4 - 6 months 5 16.7 10 33.3 
>12 months 2 6.7 2 6.7 
9. Duration of 
treatment 
0 -1 months 26 86.7 25 83.3 F=0.13 
p=0.71 1 - 6 months 4 13.3 5 16.7 
 
*  Significant at S 
** +LJKO\VLJQLILFDQWDWS 
***   Very KLJKO\VLJQLILFDQWDWS 
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Table 4.1 shows demographical data and clinical variables of head and 
neck cancer patients with oral mucositis who participated in the study. 
Regarding age,    
Majority of the subjects were between 51-65 years of age in 
experimental group (50%) and control group (40%).  
Regarding gender,  
Males were majority (83.3%) in experimental group and control group 
(80%). 
Regarding religion,  
Hindus were majority affected in both experimental group (86.7%) and 
control group (83.3%). 
Regarding educational status,  
Majority were primary school (56.7%) in experimental group and 
(63.3%) in control group. 
Regarding family monthly income,  
Majority were earning (Rs.5001-1000), in experimental group (66.6%) 
and control group (50%). 
Regarding personal habits, 
 Majority were alcoholic and smoking in experimental group (56.7%) 
and in control group (36.6%). 
According family history of cancer, majority does not have family 
history of cancer, in experimental group (96.7%) and control group (93.3%). 
According to duration of illness majority were 0-3 months in 
experimental group (76.6%) and in control group (60%). 
According to duration of treatment majority are 0-1 month in 
experimental group (86.7%) and in control group (83.3%).  
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Section-B:  Assess for oral mucositis of the patients with head and 
neck cancer of both experimental and control group. 
Table 4.2 Pre test level of oral mucositis (ulceration, erythema, pain and 
ability to swallow) 
S.No Items of oral mucositis 
Experimental 
group 
Control 
group Chi 
square 
test 
f % f % 
1. 
 
Ulceration 
No lesion 1 3.3 2 6.7 F2=1.36 
 p=0.71  
 
 Mild 9 30.0 9 30.0 
 Moderate 17 56.7 18 60.0 
 Severe 3 10.0 1 3.3 
Total 30 100.0 30 100.0 
2 Erythema  F2=1.01 
 p=0.80 
 
No lesion 1 3.3 2 6.7 
Mild 8 26.7 10 33.3 
Moderate 19 63.3 17 56.7 
Severe 2 6.7 1 3.3 
Total 30 100.0 30 100.0 
3. Pain  F2=2.53 
p=0.28 
 
No pain 0 0.0 0 0.0 
Mild 13 43.3 17 56.6 
Moderate 11 36.7 11 36.7 
Severe 6 20.0 2 6.7 
Total 30 100.0 30 100.0 
4. Ability to swallow F2=1.51 p=0.46 
Able to swallow foods 
without pain 3 10.0 2 6.7 
Able to swallow with pain 22 73.3 25 83.3 
Requires intravenous 
rehydration 5 16.7 3 10.0 
Total 30 100.0 30 100.0 
 
 *  Significant at S 
** +LJKO\VLJQLILFDQWDWS 
***   Very KLJKO\VLJQLILFDQWDWS 
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Table 4.2 shows that prevalence of ulceration, erythema, pain and 
ability to swallow in oral mucositis was equally distributed in both 
experimental group and control group. 
In ulceration - Among experimental group (30 patients), 1(3.3%) did 
not have any lesion, 9(30.0%) had mild score, 17(56.7%) had moderate score 
and 3(10.0%) had severe ulceration score. Among control group (30 patients), 
2(6.7%) did not have any lesion, 9(30.0%) had mild score, 18(60.0%) had 
moderate score and 1(3.3%) had severe ulceration score. 
In Erythema - Among experimental group (30 patients), 1(3.3%) 
patients did not have any lesion, 8(26.7%) had mild score, 19(63.3%) had 
moderate score and 2(6.7%) had severe erythema score.  Among control group, 
2(6.7%) did not have any lesion, 10(33.3%) had mild score, 17(56.7%) had 
moderate score and 1(3.3%) had severe Erythema score. 
In pain - Among experimental group, 13(43.3%) patients had mild 
score, 11(36.7%) had moderate score and 6(20.0%) had severe pain score. 
Among control group, 17(56.7%) had mild score, 11(36.7%) had moderate 
score and 2(6.7%) had severe pain score. 
In ability to swallow - Among experimental group, 3(10.0%) patients 
were able to swallow foods without pain, 22(73.3%) were able to swallow with 
pain, and 5(16.7%) were requiring intravenous rehydration. Among control 
group, 2(6.7%) were able to swallow foods without pain, 25(83.3%) were able 
to swallow with pain, and 3(10.0%) were requiring intravenous rehydration.  
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Section-C: Assess effectiveness of apitherapy for the patients with 
head and neck cancer of experimental group. 
Table 4.3 Post test level of oral mucositis (ulceration, erythema, pain and 
ability to swallow) 
S.No Items of oral mucositis 
Experimental 
group 
Control 
group 
Chi square 
test 
f % f % 
1. Ulceration F2=8.16  
p=0.02* 
 
No lesion 9 30.0 3 10.0 
 Mild 15 50.0 11 36.7 
 Moderate 6 20.0 16 53.3 
 Severe 0 0.0 0 0.0 
Total 30 100.0 30 100.0 
2. Erythema   F2=16.52  
p=0.001*** 
 
No lesion 13 43.3 3 10.0 
Mild 15 50.0 12 40.0 
Moderate 2 6.7 15 50.0 
Severe 0 0.0 0 0.0 
Total 30 100.0 30 100.0 
3. Pain  F2=15.94 
p=0.001*** 
 
No pain 17 56.7 3 10.0 
Mild 11 36.7 18 60.0 
Moderate 2 6.7 9 30.0 
Severe 0 0.0 0 0.0 
Total 30 100.0 30 100.0 
4. Ability to swallow F2=13.49 
p=0.001*** 
 
Able to swallow without pain 16 53.3 3 10.0 
Able to swallow with pain 14 46.7 26 86.7 
Requires intravenous rehydration 0 0.0 1 3.3 
Total 30 100.0 30 100.0 
  
 *  Significant at S 
** Highly significant DWS 
***   Very KLJKO\VLJQLILFDQWDWS 
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Table 4.3 shows effectiveness of apitherapy by comparing the post test 
level of oral mucositis among experimental group and control group. 
 In Ulceration - Among experimental group, 9(30.0%) patients did not 
have any lesion, 15(50.0%) had mild score, and 6(20.0%) had moderate score. 
Among control group, 3(10.0%) did not have any lesion, 11(36.7%) had mild 
score, and 16(53.3%) had moderate score.  
In Erythema - among experimental group, 13(43.3%) patients did not 
have any lesion, 15(50.0%) had mild score, and 2(6.7%) had moderate score. 
Among control, 3(10.0%) did not have any lesion, 12(40.0%) had mild score, 
and 15(50.0%) had moderate score. 
In Pain - among experimental, 17(56.7%) patients did not have any 
pain, 11(36.7%) had mild pain score, and 2(6.6%) had moderate pain score. 
Among control group, 3(10%) did not have any pain, 18(60.0%) had mild pain 
score, and 9(30.0%) had moderate score. 
In Ability to swallow - among experimental group, 16(53.3%) were 
able to swallow foods without pain, 14(46.7%0 were able to swallow with pain. 
Among control group, 3(10%) were able to swallow foods without pain, 
26(86.7%) were able to swallow with pain, and 1(3.3%) were requiring 
intravenous rehydration.  
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Section-D: Compare the pre test and post test level of oral mucositis 
among head and neck cancer patients in experimental group and 
control group. 
Table 4.4 Pre test and post test level of oral mucositis (ulceration, 
erythema, pain and ability to swallow) in experimental group 
S.No Items of oral mucositis 
Pre test Post test Chi square 
test 
f % f % 
1. Ulceration F2=16.16  
p=0.001**  
 
No lesion 1 3.3 9 30.0 
Mild 9 30.0 15 50.0 
Moderate 17 56.7 6 20.0 
Severe 3 10.0 0 0.0 
Total 30 100.0 30 100.0 
2. Erythema   
F2=28.17 
p=0.001*** 
 
No lesion 1 3.3 13 43.3 
Mild 8 26.7 15 50.0 
Moderate 19 63.3 2 6.7 
Severe 2 6.7 0 0.0 
Total 30 100.0 30 100.0 
3. Pain F2=29.39 
p=0.001*** No pain 0 0.0 17 56.7 
 Mild 13 43.3 11 36.7 
 Moderate 11 36.7 2 6.6 
 Severe 6 20.0 0 0.0 
Total 30 100.0 30 100.0 
4. Ability to swallow F2=15.67 
p=0.001*** Able to swallow without pain 3 10.0 16 53.3 
Able to swallow with pain 22 73.3 14 46.7 
Requires intravenous 
rehydration 5 16.7 0 0.0 
Total 30 100.0 30 100.0 
* Significant    p  0.01 
** Highly significant  p  0.001 
***  Very highly significant S 
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Table 4.4 shows level of oral mucositis among patients in experimental group 
before and after apitherapy 
 In experimental group (30 patients), 
On assessing pre test level of ulceration, 1(3.3%) did not have any 
lesion, 9(30.0%) had mild score, 17(56.7%) had moderate score and 3(10.0%) 
had severe ulceration score.  In post test level of ulceration, 9(30.0%) did not 
have any lesion, 15(50.0%) had mild score, 6(20.0%) had moderate score. 
Hence post test level of ulceration (p=0.001**) was highly significant 
In pre test level of erythema, 1(3.3%) did not have any lesion, 8(26.7%) 
had mild score, 19(63.3%) had moderate score and 2(6.7%) had severe 
erythema score.  In post test level of erythema, 13(43.3%) did not have any 
lesion, 15(50.0%) had mild score, 2(6.7%) had moderate score. Hence post test 
level of erythema (p=0.001***) was very highly significant. 
In pre test level of pain, 13(43.3%) had mild score, 11(36.7%) had 
moderate score and 6(20.0%) had severe pain score.  In post test level of pain, 
17(56.7%) did not have any lesion, 11(36.7%) had mild score, 2(6.6%) had 
moderate score. Hence post test level of pain (p=0.001***) was very highly 
significant. 
In pre test level of ability to swallow, 3(10.0%) were able to swallow 
foods without pain, 22(73.3%) were able to swallow with pain, and 5(16.7%) 
were requiring intravenous rehydration. In post test level of ability to swallow, 
16(53.3%) were able to swallow foods without pain, 14(46.7%) were able to 
swallow with pain. Hence post test level of ability to swallow (p=0.001***) 
was very highly significant. 
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Table 4.5 Pre test and post test level of oral mucositis (ulceration, 
erythema, pain and ability to swallow) in control group 
S.No Items of oral mucositis 
Pre test Post test Chi 
square 
test f % f % 
1. 
 
Ulceration 
F2=1.51  
p=0.67  
No lesion 2 6.7 3 10.0 
Mild 9 30.0 11 36.7 
Moderate 18 60.0 16 53.3 
Severe 1 3.3 0 0.0 
Total 30 100.0 30 100.0 
2. Erythema  
F2=1.50  
p=0.68 
No lesion 2 6.7 3 10.0 
Mild 10 33.3 12 40.0 
Moderate 17 56.7 15 50.0 
Severe 1 3.3 0 0.0 
Total 30 100.0 30 100.0 
3. Pain  
F2=5.22 
 p=0.16 
No pain 0 0.0 3 10.0 
Mild 17 56.6 18 60.0 
Moderate 11 36.7 9 30.0 
Severe 2 6.7 0 0.0 
Total 30 100.0 30 100.0 
4.  Ability to swallow      
F2=1.21 
 p=0.52 
Able to swallow foods without pain 2 6.7 3 10.0 
Able to swallow with pain 25 83.3 26 86.7 
Requires intravenous rehydration 3 10.0 1 3.3 
Total 30 100.0 30 100.0 
  
*  Significant at S 
The above table represents the pre test and post test levels of oral 
mucositis among control group in which there was no significant change in 
ulceration, erythema, pain and ability to swallow. 
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Section-E: Association between post test level of oral mucositis 
among head and neck cancer patients with selected demographic 
variables. 
Table 4.6 Association between post test level of ulceration and patients 
demographic variables (experimental group) 
S.No Demographic variables 
Post test level of Ulceration 
Total 
Chi 
square 
test 
No 
lesion Mild Moderate 
f % f % f % 
1. Age  
  
  
21 -35 years 0  0.0  1 33.3 2 66.7 3 
F2=10.53  
p=0.03* 36 -50 years 2 16.7 6 50.0 4 33.3 12 51 -65 years 7 46.7 8 53.3 0  0.0  15 
2. Sex 
  
Male 9 36.0 12 48.0 4 16.0 25 F2=3.12 
 p=0.21 Female 0 0  3 60.0 2 40.0 5 
3. Religion 
  
  
Hindu 9 34.6 12 46.2 5 19.2 26 F2=7.26 
p=0.12 Christian 0  0  3 100 0  0  3 Muslim 0  0  0  00  1 100 1 
4. Educational 
qualification 
  
No formal 
education 1 20.0 3 60.0 1 20.0 5 
F2=2.63  
p=0.25 
Upto Primary 
level 5 29.4 9 52.9 3 17.6 17 
Upto middle 
school level 3 42.9 2 28.6 2 28.6 7 
Higher 
secondary level 0  0  1 100 0  0  1 
5. Income per 
month 
  
< Rs.5,000 3 37.5 3 37.5 2 25.0 8 
F2=2.35  
p=0.67 
Rs.5,001 - 
10,000 6 30.0 11 55.0 3 15.0 20 
Rs.10,001 - 
15,000 0  0.0  1 50.0 1 50.0 2 
6. Personal 
habits 
  
  
  
  
Smoking 1 33.3 2 66.7 0  0.0  3 
F2=9.86  
p=0.27 
Alcohol 0  0.0  1 100 0  0.0  1 
Smoking and 
alcohol 8 47.1 7 41.2 2 11.8 17 
Other tobacco 
products 0  0.0  2 50.0 2 50.0 4 
No habit of 
tobacco or 
alcohol abuse 
0  0.0  3 60.0 2 40.0 5 
7. Family 
history of 
cancer 
Yes 1 100 0  0.0  0  0.0  1 F2=1.41  
p=0.29 No 8 27.6 15 51.7 6 20.7 29 
8. Duration of 
illness 
0 - 3 months 7 30.4 13 56.5 3 13.0 23 
F2=10.62  
p=0.03* 4 - 6 months 2 40.0 2 40.0 1 20.0 5 >12 months 0 50.0 0 0.0 2  100  2 
9. Duration of 
treatment 
0 -1 months 9 34.6 13 50.0 4 15.4 26 F2=3.46 
p=0.18 1 - 6 months 0  0.0  2 50.0 2 50.0 4 
* Significant      S   
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Table 4.6 shows the association between post test level of oral mucositis 
(ulceration) after apitherapy among head and neck cancer patients undergoing 
radiation therapy with selected demographic variables in experimental group.  
Demographic variables - Elders and less duration of illness patients 
among experimental group have association with post test level of ulceration. 
Statistical significance was calculated using chi square test. 
Gender, religion, educational qualification, income per month, personal 
habits, family history of cancer, and duration of treatment does not have 
significance with degree of oral mucositis (post test level of ulceration).  
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Table 4.7 Association between post test level of ulceration and patients 
demographic variables (control group) 
S.No Demographic variables 
Post test level of Ulceration 
Total 
Chi 
square 
test 
No 
lesion Mild Moderate 
f % f % f % 
1. Age  21 -35 years 0 0  1 25.0 3 75.0 4 
F2=1.97 
p=0.74 
36 -50 years 1 7.1 5 35.7 8 57.1 14 
51 -65 years 2 16.7 5 41.7 5 41.7 12 
2. Sex 
  
Male 2 8.3 9 37.5 13 54.2 24 F2=0.37 
p=0.83 Female 1 16.7 2 33.3 3 50.0 6 
3. Religion 
  
  
Hindu 3 12.0 9 36.0 13 52.0 25 
F2=0.82 
p=0.93 
Christian 0 0  1 33.3 2 66.7 3 
Muslim 0 0  1 50.0 1 50.0 2 
4. Educational 
qualification 
  
No formal education 0 0  1 20.0 4 80.0 5 
F2=8.61 
p=0.19 
Upto Primary level 1 5.3 9 47.4 9 47.4 19 
Upto middle school 
level 2 40.0 1 20.0 2 40.0 5 
Higher secondary 
level 0  0 0   0 1 100 1 
5. Income per 
month 
< Rs.5,000 1 7.7 3 23.1 9 69.2 13 
F2=2.71 
p=0.61 
Rs.5,001 - 10,000 2 13.3 7 46.7 6 40.0 15 
Rs.10,001 - 15,000 0 0  1 50.0 1 50.0 2 
6. Personal 
habits 
  
  
  
  
Smoking 0 0  4 80.0 1 20.0 5 
F2=11.56 
p=0.17 
Alcohol 0  0 1 50.0 1 50.0 2 
Smoking and alcohol 0  0 2 18.2 9 81.8 11 
Other tobacco 
products 1 20.0 2 40.0 2 40.0 5 
No habit of tobacco 
or alcohol abuse 2 28.6 2 28.6 3 42.9 7 
7. Family 
history of 
cancer 
Yes 0  0 1 50.0 1 50.0 2 F2=0.32 
p=0.85 No 3 10.7 10 35.7 15 53.6 28 
8. Duration 
of illness 
0 - 3 months 2 11.1 7 38.9 9 50.0 18 F2=1.88 
p=0.76 
 
4 - 6 months 1 10.0 4 40.0 5 50.0 10 
>12 months 0  0 0  0  2 100 2 
9. Duration 
of 
treatment  
0 -1 months 3 12.0 7 28.0 15 60.0 25 F2=4.92 
p=0.09 1 - 6 months 0 0  4 80.0 1 20.0 5 
*  Significant at S 
The above table shows that there was no between post test level of oral 
mucositis (ulceration) among head and neck cancer patients undergoing 
radiation therapy with selected demographic variables in control group.
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Table 4.8 Association between post test level of erythema and patients 
demographic variables (experimental group) 
S.No Demographic variables 
Post test level of Erythema 
Total 
Chi 
square 
test 
No lesion Mild Moderate 
f % f % f % 
1. Age  21 -35 years 2 66.7 1 33.3 0  0  3 
F2=1.30 
 p=0.86 36 -50 years 4 33.3 7 58.3 1 8.3 12 51 -65 years 7 46.7 7 46.7 1 6.7 15 
2. Sex Male 10 40.0 13 52.0 2 8.0 25 F2=0.90  
p=0.63 Female 3 60.0 2 40.0 0 0  5 
3. Religion 
  
  
Hindu 12 46.2 12 46.2 2 7.7 26 F2=4.47 
p=0.34 
 
Christian 0  0  3 100.0 0  0  3 
Muslim 1 100 0  0  0 0  1 
4. Educational 
qualification 
 
No formal 
education 3 60.0 1 20.0 1 20.0 5 
F2=7.23 
p=0.30 
Upto Primary 
level 6 35.3 11 64.7 0 0  17 
Upto middle 
school level 4 57.1 2 28.6 1 14.3 7 
Higher 
secondary level 0  0  1 100.0 0  0  1 
5. Income per 
month 
< Rs.5,000 4 50.0 2 25.0 2 25.0 8 
F2=7.05 
p=0.13 
Rs.5,001 - 
10,000 8 40.0 12 60.0 0  0  20 
Rs.10,001 - 
15,000 1 50.0 1 50.0 0  0  2 
6. Personal 
habits 
Smoking 1 33.3 2 66.7 0  0  3 
F2=3.20 
p=0.92 
 
Alcohol 0  0  1 100.0 0  0  1 
Smoking and 
alcohol 7 41.2 8 47.1 2 11.8 17 
Other tobacco 
products 2 50.0 2 50.0 0  0  4 
No habit of 
tobacco or 
alcohol abuse 
3 60.0 2 40.0 0  0  5 
7. Family 
history of 
cancer 
Yes 0  0.0  0  0.0  1 100 1 F2=1.45 
p=0.20 
 No 13 44.8 15 51.7 1 3.4 29 
8. Duration 
of illness 
  
0 - 3 months 11 47.8 12 52.2 0  0.0  23 F2=9.60 
p=0.05* 
 
4 - 6 months 2 40.0 2 40.0 1 20.0 5 
>12 months 0  0.0  1 50.0 1 50.0 2 
9. Duration of 
treatment 
0 -1 months 13 50.0 12 46.1 1 3.9 26 F2=6.63 
p=0.05* 1 - 6 months 0 0.0 3 75.0 1  25.0  4 
* Significant      S   
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Table 4.8 shows the association between post test level of oral mucositis 
(erythema) after apitherapy among head and neck cancer patients undergoing 
radiation therapy with selected demographic variables in experimental group 
Demographic variables - less duration of illness and less duration of 
treatment patients among experimental group have association with post test 
level of erythema. Statistical significance was calculated using chi square test. 
Age, sex, religion, educational qualification, income per month, 
personal habits, and family history of cancer does not have significance with 
degree of oral mucositis (post test level of erythema). 
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Table 4.9 Association between level of erythema and patients demographic 
variables (control) 
S.No Demographic variables 
Post test level of Erythema 
Total 
Chi 
square 
test 
No 
lesion Mild Moderate 
f % f % f % 
1. Age  21 -35 years 1 25.0 1 25.0 2 50.0 4 F2=3.97 
 p=0.40 
 
36 -50 years 1 7.1 4 28.6 9 64.3 14 
51 -65 years 1 8.3 7 58.3 4 33.3 12 
2. Sex Male 3 12.5 9 37.5 12 50.0 24 F2=0.93 
 p=0.62 Female 0  0  3 50.0 3 50.0 6 
3. Religion  Hindu 2 8.0 11 44.0 12 48.0 25 
F2=3.47 
p=0.48 Christian 1 33.3 0  0  2 66.7 3 Muslim 0  0  1 50.0 1 50.0 2 
4. Educational 
qualification  
No formal 
education 0 0  2 40.0 3 60.0 5 
F2=3.41 
 p=0.75 
Upto Primary level 3 15.8 7 36.8 9 47.4 19 
Upto middle school 
level 0  0  3 60.0 2 40.0 5 
Higher secondary 
level 0  0  0  0  1 100 1 
5. Income per 
month  
< Rs.5,000 1 7.7 6 46.2 6 46.2 13 
F2=0.84  
p=0.91 Rs.5,001 - 10,000 2 13.3 5 33.3 8 53.3 15 Rs.10,001 - 15,000 0  0  1 50.0 1 50.0 2 
6. Personal 
habits  
Smoking 0  0  3 60.0 2 40.0 5 
F2=9.66  
p=0.28 
Alcohol 1 50.0 0  0  1 50.0 2 
Smoking and 
alcohol 0  0  3 27.3 8 72.7 11 
Other tobacco 
products 1 20.0 2 40.0 2 40.0 5 
No habit of tobacco 
or alcohol abuse 1 14.3 4 57.1 2 28.6 7 
7. Family 
history of 
cancer 
Yes 0  0  0  0  2 100 2 F2=2.14 
p=0.33 No 3 10.7 12 42.9 13 46.4 28 
8. Duration 
of illness  
0 - 3 months 3 16.7 6 33.3 9 50.0 18 
F2=5.20  
p=0.26 4 - 6 months 0  0  6 60.0 4 40.0 10 >12 months 0  0      2 100 2 
9. Duration of 
treatment 
0 -1 months 3 12.0 9 36.0 13 52.0 25 F2=1.32 
 p=0.52 1 - 6 months 0  0  3 60.0 2 40.0 5 
*  Significant at S 
The above table shows that there was no association between post test 
level of oral mucositis (erythema) among head and neck cancer patients 
undergoing radiation therapy with selected demographic variables in control 
group. 
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Table 4.10 Association between post test level of pain and patients 
demographic variables (Experimental group) 
S.No Demographic variables 
Post test level of Pain 
Total 
Chi 
square 
test 
No pain Mild Moderate 
f % f % f % 
1. Age  21 -35 years 1 33.3 0  0.0  2 66.7 3 
F2=20.37 
p=0.01* 
36 -50 years 6 50.0 6 50.0 0  0.0  12 
51 -65 years 10 66.7 5 33.3 0  0.0  15 
2. Sex  Male 16 64.0 8 32.0 1 4.0 25 F2=3.91 
 p=0.14 Female 1 20.0 3 60.0 1 20.0 5 
3. Religion  Hindu 14 53.8 10 38.5 2 7.7 26 
F2=1.12 
p=0.89 
Christian 2 66.7 1 33.3 0  0.0  3 
Muslim 1 100 0  0.0  0  0.0  1 
4. Educational 
qualification 
No formal education 3 60.0 2 40.0 0  0  5 
F2=3.01 
p=0.89 
Upto Primary level 8 47.1 7 41.2 2 11.8 17 
Upto middle school 
level 5 71.4 2 28.6 0  0  7 
Higher secondary 
level 1 100 0  0  0  0  1 
5. Income per 
month  
< Rs.5,000 3 37.5 4 50.0 1 12.5 8 
F2=2.91 
p=0.56 
Rs.5,001 - 10,000 12 60.0 7 35.0 1 5.0 20 
Rs.10,001 - 15,000 2 100 0  0  0  0  2 
6. Personal 
habits 
  
  
  
  
Smoking 3 100 0  0.0  0  0.0  3 
F2=12.16 
p=0.14 
Alcohol 0  0.0  1 100 0  0.0  1 
Smoking and alcohol 12 70.6 5 29.4 0  0.0  17 
Other tobacco 
products 1 25.0 2 50.0 1 25.0 4 
No habit of tobacco 
or alcohol abuse 1 20.0 3 60.0 1 20.0 5 
7. Family 
history of 
cancer  
Yes 0  0.0  1 100 0  0.0  1 F2=1.78 
p=0.40 No 17 58.6 10 34.5 2 6.9 29 
8. Duration 
of illness  
0 - 3 months 15 65.2 7 30.4 1 4.3 23 
F2=10.37 
p=0.05* 
4 - 6 months 2 40.0 3 60.0 0  0.0  5 
>12 months 0  0.0  1 50.0 1 50.0  2 
9. Duration of 
treatment  
0 -1 months 16 61.5 8 30.8 2 7.7 26 F2=2.94 
p=0.21 1 - 6 months 1 25.0 3 75.0 0  0.0  4 
      
* Significant      S   
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Table 4.10 shows the association between post test level of oral 
mucositis (pain) after apitherapy among head and neck cancer patients 
undergoing radiation therapy with selected demographic variables.  
Demographic variables - Less duration of illness and elder patients 
among experimental group have association with post test level of pain.  
Sex, religion, educational qualification, income per month, personal 
habits, family history of cancer and duration of treatment does not have 
significance with degree of oral mucositis (post test level of pain). 
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Table 4.11 Association between level of pain and patients demographic 
variables (control group) 
S.No Demographic variables 
Post test level of Pain 
Total 
Chi 
square 
test No pain Mild Moderate f % f % f % 
1. Age   21 -35 years 0 0  2 50.0 2 50.0 4 F2=6.01 
 p=0.19  36 -50 years 0 0  9 64.3 5 35.7 14  51 -65 years 3 25.0 7 58.3 2 16.7 12 
2. Sex  Male 1 4.2 15 62.5 8 33.3 24 F2=4.65  
p=0.10  Female 2 33.3 3 50.0 1 16.7 6 
3. Religion  Hindu 3 12.0 16 64.0 6 24.0 25 F2=2.97 
p=0.56  Christian 0  0  1 33.3 2 66.7 3  Muslim 0  0  1 50.0 1 50.0 2 
4. Educational 
qualification 
No formal education 2 40.0 2 40.0 1 20.0 5 
F2=11.21  
p=0.08 
 Upto Primary level 0  0  15 78.9 4 21.1 19 
 Upto middle school 
level 1 20.0 1 20.0 3 60.0 5 
 Higher secondary 
level 0  0  0  0  1 100 1 
5. Income 
per month  
< Rs.5,000 0  0  10 76.9 3 23.1 13 
F2=4.62 
p=0.36  Rs.5,001 - 10,000 3 20.0 7 46.7 5 33.3 15  Rs.10,001 - 15,000 0 0  1 50.0 1 50.0 2 
6. Personal 
habits  
Smoking 1 20.0 4 80.0 0  0  5 
F2=7.35 
p=0.48 
 Alcohol 0  0  1 50.0 1 50.0 2 
 Smoking and 
alcohol 0  0  7 63.6 4 36.4 11 
 Other tobacco 
products 0  0  3 60.0 2 40.0 5 
 No habit of tobacco 
or alcohol abuse 2 28.6 3 42.9 2 28.6 7 
7. Family 
history of 
cancer  
Yes 0  0  1 50.0 1 50.0 2 F2=0.53 
p=0.76  No 3 10.7 17 60.7 8 28.6 28 
8. Duration 
of illness  
0 - 3 months 1 5.6 12 66.7 5 27.8 18 F2=5.22 
p=0.25  4 - 6 months 0  0  6 60.0 4 40.0 10  >12 months 2 100 0   0 0  0  2 
9. Duration of 
treatment  
0 -1 months 3 12.0 14 56.0 8 32.0 25 F2=1.20 
p=0.54  1 - 6 months 0  0  4 80.0 1 20.0 5 
*  Significant at S 
The above table shows that there was no association between post test 
level of oral mucositis (pain) after apitherapy among head and neck cancer 
patients undergoing radiation therapy with selected demographic variables in 
control group.  
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Table 4.12 Association between post test level of ability to swallow and 
patients demographic variables (Experimental group) 
S.No Demographic variables  
Post test level of 
ability to swallow 
Total 
Chi 
square 
test 
Able to 
swallow 
without 
pain 
Able to 
swallow 
with pain 
f % f % 
1. Age  21 -35 years 2 66.7 1 33.3 3 
F2=0.60  
p=0.74 
 36 -50 years 7 58.3 5 41.7 12 
 51 -65 years 7 46.7 8 53.3 15 
2. Sex Male 16 64.0 9 36.0 25 F2=9.52 
p=0.05*  Female 0 00.0 5 100.0 5 
3. Religion Hindu 15 57.7 11 42.3 26 
F2=4.50 
p=0.10 
 Christian 0  0  3 100.0 3 
 Muslim 1 100 0  0  1 
4. Educational 
qualification 
No formal education 1 20.0 4 80.0 5 
F2=4.51  
p=0.21 
 Upto Primary level 10 58.8 7 41.2 17 
 Upto middle school 
level 5 71.4 2 28.6 7 
 Higher secondary 
level 0  0  1 100.0 1 
5. Income per 
month 
< Rs.5,000 3 37.5 5 62.5 8 
F2=1.17  
p=0.57 
 Rs.5,001 - 10,000 12 60.0 8 40.0 20 
 Rs.10,001 - 15,000 1 50.0 1 50.0 2 
6. Personal 
habits 
Smoking 2 66.7 1 33.3 3 
F2=2.94 
 p=0.56 
 Alcohol     1 100.0 1 
 Smoking and alcohol 10 58.8 7 41.2 17 
 Other tobacco 
products 1 25.0 3 75.0 4 
 No habit of tobacco 
or alcohol abuse 3 60.0 2 40.0 5 
7. Family 
history of 
cancer 
Yes 1 100 0  0  1 F2=0.90  
p=0.34  No 15 51.7 14 48.3 29 
8. Duration of 
illness 
0 - 3 months 15 65.2 8 34.8 23 
F2=5.84 
p=0.05* 
 4 - 6 months 1 20.0 4 80.0 5 
 >12 months 0 0.0 2 100.0 2 
9. Duration of 
treatment 
0 -1 months 13 50.0 13 50.0 26 F2=0.87 
p=0.35  1 - 6 months 3 75.0 1 25.0 4 
 
* Significant      S   
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Table 4.12 shows the association between post test level of oral 
mucositis (ability to swallow) after apitherapy among head and neck cancer 
patients undergoing radiation therapy with selected demographic variables in 
experimental group.   
Demographic variables - male and less duration of illness patients 
among experimental group have association with post test level of ability to 
swallow.  
Age, religion, educational qualification, income per month, personal 
habits, family history of cancer and duration of treatment does not have 
significance with degree of oral mucositis (post test level of ability to swallow). 
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Table 4.13 Association between level of ability to swallow and  patients 
demographic variables(control group) 
S.No Demographic variables 
Post test level of Ability to 
swallow 
Total 
Chi 
square 
test 
swallow 
without 
pain 
swallow 
with 
pain 
Requires 
intravenous 
rehydration 
n % n % n % 
1. Age in 
years 
21 -35 years 1 25.0 3 75.0 0  0  4 
F2=2.68  
p=0.61 36 -50 years 1 7.1 13 92.9  0 0  14 51 -65 years 1 8.3 10 83.3 1 8.3 12 
2. Sex  Male 1 4.2 22 91.7 1 4.2 24 F2=4.67  
p=0.10 Female 2 33.3 4 66.7 0  0  6 
3. Religion Hindu 3 12.0 21 84.0 1 4.0 25 F2=0.92 
p=0.92 Christian 0  0  3 100 0  0  3 Muslim 0  0  2 100 0  0  2 
4. Educational 
qualification 
No formal 
education 0  0  5 100 0  0  5 
F2=2.67 
p=0.85 
Upto Primary level 3 15.8 15 78.9 1 5.3 19 
Upto middle school 
level 0 0  5 100 0  0  5 
Higher secondary 
level 0  0  1 100 0  0  1 
5. Income 
per month  
< Rs.5,000 2 15.4 10 76.9 1 7.7 13 
F2=2.31 
p=0.68 Rs.5,001 - 10,000 1 6.7 14 93.3 0  0  15 Rs.10,001 - 15,000 0  0  2 100 0  0  2 
6. Personal 
habits 
Smoking 1 20.0 4 80.0 0  0  5 
F2=6.45 
p=0.60 
Alcohol 0  0  2 100 0  0  2 
Smoking and 
alcohol 1 9.1 10 90.9 0  0  11 
Other tobacco 
products 0  0  4 80.0 1 20.0 5 
No habit of tobacco 
or alcohol abuse 1 14.3 6 85.7 0  0  7 
7. Family 
history of 
cancer  
Yes 0  0  2 100 0  0  2 F2=0.33 
p=0.84 No 3 10.7 24 85.7 1 3.6 28 
8. Duration 
of illness  
0 - 3 months 3 16.7 14 77.8 1 5.6 18 
F2=3.07 
p=0.54 4 - 6 months 0  0  10 100 0  0  10 >12 months 0  0  2 100 0  0  2 
9. Duration of 
treatment 
0 -1 months 3 12.0 21 84.0 1 4.0 25 F2=0.92 
p=0.63 1 - 6 months 0  0  5 100 0  0  5 
*  Significant at S 
The above table shows the no association between post test level of oral 
mucositis (ability to swallow) among head and neck cancer patients undergoing 
radiation therapy with selected demographic variables in control group.  
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CHAPTER ̽ V 
SUMMARY OF RESULTS 
This chapter deals with the summary of discussion on the findings of the 
study interpreted from statistical analysis. The findings are discussed in relation 
to the objectives, need for the study, related literature review and conceptual 
frame work. 
Demographic and clinical variables of head and neck cancer patients 
The demographic variables of head and neck cancer patients with oral 
mucositis those who participated in the study were explained. Regarding the 
age, majority of the subjects were between 51-65 years of age in experimental 
group (50%) and control group (40%).  
Regarding gender, males were majority (83.3%) in experimental group 
and control group (80%). 
Regarding religion, Hindus were majority affected in both experimental 
group (86.7%) and control group (83.3%). 
Regarding educational status, majority primary school (56.7%) in 
experimental group and (63.3%) in control group. 
According to family monthly income was (Rs.5001-1000) majority in 
experimental group (66.6%) and control group (50%). 
According to personal habits majority were alcoholism and smoking in 
experimental group (56.7%) and in control group (36.6%). 
According to family history of cancer majority does not have family 
history of cancer, in experimental group (96.7%) and control group (93.3%). 
According to duration of illness majority were 0-3 months in 
experimental group (76.6%) and in control group (60%). 
According to duration of treatment majority were 0-1 month in 
experimental group (86.7%) and in control group (83.3%). 
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Level of oral mucositis of the patients with head and neck cancer of 
experimental group and control group before apitherapy. 
In ulceration - Among experimental group, 1(3.3%) patients did not 
have any lesion, 9(30.0%) had mild score, 17(56.7%) had moderate score and 
3(10.0%) had severe ulceration score.  
Among control group, 2(6.7%) did not have any lesion, 9(30.0%) had 
mild score, 18(60.0%) had moderate score and 1(3.3%) had severe ulceration 
score. 
In Erythema - Among experimental group, 1(3.3%) patients did not 
have any lesion, 8(26.7%) had mild score, 19(63.3%) had moderate score and 
2(6.7%) had severe erythema score.   
Among control group, 2(6.7%) did not have any lesion, 10(33.3%) had 
mild score, 17(56.7%) had moderate score and 1(3.3%) had severe Erythema 
score. 
In pain - Among experimental group, 13(43.3%) patients had mild 
score, 11(36.7%) had moderate score and 6(20.0%) had severe pain score.  
Among control group, 17(56.7%) had mild score, 11(36.7%) had 
moderate score and 2(6.7%) had severe pain score. 
In ability to swallow - Among experimental group, 3(10.0%) patients 
were able to swallow foods without pain, 22(73.3%) were able to swallow with 
pain, and 5(16.7%) were requiring intravenous rehydration.  
Among control group, 2(6.7%) were able to swallow foods without pain, 
25(83.3%) were able to swallow with pain, and 3(10.0%) were requiring 
intravenous rehydration.  
So, there was equal distribution of subjects among experimental group 
and control group. It was confirmed using chi square.  
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Effectiveness of apitherapy for the patients with head and neck 
cancer of experimental group. 
Effectiveness of apitherapy was assessed by comparing the post test 
level of experimental group with the control group. 
In Ulceration - Among experimental group, 9(30.0%) patients did not 
have any lesion, 15(50.0%) had mild score, and 6(20.0%) had moderate score. 
Among control group, 3(10.0%) did not have any lesion, 11(36.7%) had mild 
score, and 16(53.3%) had moderate score.  
In Erythema - among experimental group, 13(43.3%) patients did not 
have any lesion, 15(50.0%) had mild score, and 2(6.7%) had moderate score. 
Among control, 3(10.0%) did not have any lesion, 12(40.0%) had mild score, 
and 15(50.0%) had moderate score. 
In Pain - among experimental, 17(56.7%) patients did not have any 
pain, 11(36.7%) had mild score, and 2(6.6%) had moderate pain score. Among 
control group, 3(10%) did not have any pain, 18(60.0%) had mild score, and 
9(30.0%) had moderate score. 
In Ability to swallow - among experimental group, 16(53.3%) were 
able to swallow foods without pain, 14(46.7%0 were able to swallow with pain. 
Among control group, 3(10%) were able to swallow foods without pain, 
26(86.7%) were able to swallow with pain, and 1(3.3%) were requiring 
intravenous rehydration.  
Hence, there was statistically significant reduction in oral mucositis 
among patients in experimental group after apitherapy. (p=0.02 for 
ulceration, p=0.001 for erythema, p=0.001 for pain and p=0.001 for ability to 
swallow) 
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Compare the pre test and post test level of oral mucositis among head 
and neck cancer patients in experimental group and control group. 
Using chi square the effectiveness of apitherapy between experimental group 
and control group was assessed.   
In experimental group (30 patients), 
In pre test level of ulceration, 1(3.3%) did not have any lesion, 9(30.0%) 
had mild score, 17(56.7%) had moderate score and 3(10.0%) had severe 
ulceration score.  In post test level of ulceration, 9(30.0%) did not have any 
lesion, 15(50.0%) had mild score, 6(20.0%) had moderate score. Hence post 
test level of ulceration (p=0.001**) was highly significant 
In pre test level of erythema, 1(3.3%) did not have any lesion, 8(26.7%) 
had mild score, 19(63.3%) had moderate score and 2(6.7%) had severe 
erythema score.  In post test level of erythema, 13(43.3%) did not have any 
lesion, 15(50.0%) had mild score, 2(6.7%) had moderate score. Hence post test 
level of erythema (p=0.001***) was very highly significant. 
In pre test level of pain, 13(43.3%) had mild score, 11(36.7%) had 
moderate score and 6(20.0%) had severe pain score.  In post test level of pain, 
17(56.7%) did not have any lesion, 11(36.7%) had mild score, 2(6.6%) had 
moderate score. Hence post test level of pain (p=0.001***) was very highly 
significant. 
In pre test level of ability to swallow, 3(10.0%) were able to swallow 
foods without pain, 22(73.3%) were able to swallow with pain, and 5(16.7%) 
were requiring intravenous rehydration. In post test level of ability to swallow, 
16(53.3%) were able to swallow foods without pain, 14(46.7%) were able to 
swallow with pain. Hence post test level of ability to swallow (p=0.001***) 
was very highly significant. 
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 In control group, the pre test and post test effectiveness was 
assessed which shows ulceration (p=0.67), erythema (p=0.68), pain (p=0.16) 
and ability to swallow (p=0.52) were statistically not significant.  
Association between post test level of oral mucositis among head and 
neck cancer patients with selected demographic variables. 
Association between demographic variables and their post test level of 
ulceration in experimental group showed that elders and less duration of 
illness were closely associated (F2=10.53 p=0.03* & F2=10.62 p=0.03*). 
None of the variables were associated with their level of ulceration in control 
group. 
Association between demographic variables and their post test level of 
erythema in experimental group showed that less duration of illness and less 
duration of treatment were closely associated (F2=9.60 p=0.05* & F2=6.63 
p=0.05*). None of the variables were associated with their level of erythema in 
control group. 
Association between demographic variables and their post test level of 
pain in experimental group showed that elders and less duration of illness were 
closely associated (F2=20.37 p=0.01* & F2=10.37 p=0.05*). None of the 
variables were associated with their level of pain in control group. 
Association between demographic variables and their post test level of 
ability to swallow in experimental group showed that male and less duration of 
illness were closely associated (F2=9.52p=0.05* & F2=5.84p=0.05*). None of 
the variables were associated with their level of ability to swallow in control 
group. 
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CHAPTER - VI 
DISCUSSION 
 This chapter presents the interpretation of the statistical findings with 
other co related similar studies from literature reviewed  
The aim of the study was to evaluate the effectiveness of apitherapy in 
reducing oral mucositis among head and neck cancer patients undergoing 
radiation therapy. A sample consist of 60 head and neck cancer patients 
undergoing radiation therapy who met the inclusion criteria were selected for 
the study by using simple random sampling method. Apitherapy given from 
23rd day to 36th day (about 14 days) to the experimental group and routine 
care to control group. Pre test & Post test done by using NCI-CTC scale.  
Objective 1: To assess for oral mucositis among patients with head and 
neck cancer. 
In ulceration, the difference between experimental group and control 
group was small (F2=1.36 p=0.71) & it was not significant. In Erythema, the 
difference between experimental group and control group was small (F2=1.01 
p=0.80) & it was not significant. 
In pain, the difference between experimental group and control group 
was small (F2=2.53 p=0.28) & it was not significant. In ability to swallow, the 
difference between experimental group and control group was small (F2=1.51 
p=0.46) & it was not significant. 
So, there was equal distribution of subjects among experimental group 
and control group.  
Objective 2: To assess effectiveness of apitherapy for the patients with 
head and neck cancer of experimental group. 
Effectiveness of apitherapy was assessed by comparing the post test 
level of experimental group with the control group.  
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In Ulceration -9(30.0%) of patients in experimental group and 3(10.0%) 
in control group did not have any lesion of ulceration. The difference between 
experimental and control group after apitherapy was statistically significant 
(p=0.02*) 
In Erythema - 13(43.3%) of patients in experimental group and 
3(10.0%) in control group did not have any lesion of erythema. The difference 
between experimental and control group after apitherapy was statistically 
significant (p=0.001***) 
In Pain - 17(56.7%) of patients in experimental group and 3(10.0%) in 
control group did not have any pain. The difference between experimental and 
control group after apitherapy was statistically significant (p=0.001***) 
In Ability to swallow - 16(53.3%) of patients in experimental group and 
3(10.0%) in control group were able to swallow without pain. The difference 
between experimental and control group after apitherapy was statistically 
significant (p=0.001***) 
There was statistically significant reduction in oral mucositis among 
head and neck cancer patients in experimental group after apitherapy. Hence 
hypothesis (H1) has been accepted.   
 This finding is consistent with the findings of 5DVKDG80HWµDO 
conducted a cohort study on honey as topical prophylaxis against 
radiochemotherapy induced mucositis in head and neck cancer. The aim of the 
study was to evaluate the efficacy of pure natural honey as against 
radiochemotherapy induced mucositis. In the results in the treatment group, no 
patients developed grade four mucositis and only 3 patients (15%) developed 
grade three mucositis. In the control group 13 patients (65%) developed grade 
three or four mucositis (p< 0.05). As a conclusion this study shows that 
prophylactic use of pure natural honey was effective in reducing mucositis 
resulting from radiochemotherapy in patients with head and neck cancer.  
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Objective 3: To compare the pre test and post test level of oral mucositis 
among head and neck cancer patients in experimental group and 
control group.  
In experimental group, on comparing the pre test and post test level of 
oral mucositis there was significant reduction in level of ulceration (F2=16.16 
p=0.001**), level of erythema (F2=28.17 p=0.001***), level of pain 
(F2=29.39 p=0.001***) and level of ability to swallow (F2=15.67 
p=0.001***). 
In control group, on comparing the pre test and post test level of oral 
mucositis there was no significant reduction in level of ulceration (F2=1.51 
p=0.67), level of erythema (F2=1.50 p=0.68), level of pain (F2=5.22 p=0.16), 
level of ability to swallow (F2=1.21 p=0.52). 
On comparing the pre test and post test level of oral mucositis among 
head and neck cancer patients in experimental group and control group, there 
was statistically significant reduction in oral mucositis after apitherapy in 
experimental group than control group.  
This finding is consistent with the findings of Biswa Mohan Biswal et 
µDOconducted an experimental study to evaluate the effect of pure honey 
on radiation induced mucositis. The main result of the study was there was 
significant reduction of symptomatic grade 3 mucositis among honey ± treated 
patients compared to controls. i.e. 20% versus 75% (p 0.00058). As a 
conclusion topical application of natural honey is a simple and cost- effective 
treatment in radiation mucositis.  
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Objective 4: To find the association between post test level of oral 
mucositis among head and neck cancer patients with selected 
demographic variables. 
Association between demographic variables and their post test level of 
ulceration in experimental group showed that elders and less duration of 
illness were closely associated (F2=10.53 p=0.03* & F2=10.62 p=0.03*). 
None of the variables were associated with their level of ulceration in control 
group. 
Association between demographic variables and their post test level of 
erythema in experimental group showed that less duration of illness and less 
duration of treatment were closely associated (F2=9.60 p=0.05* & F2=6.63 
p=0.05*). None of the variables were associated with their level of erythema in 
control group. 
Association between demographic variables and their post test level of 
pain in experimental group showed that elders and less duration of illness were 
closely associated (F2=20.37 p=0.01* & F2=10.37 p=0.05*). None of the 
variables were associated with their level of pain in control group. 
Association between demographic variables and their post test level of 
ability to swallow in experimental group showed that male and less duration of 
illness were closely associated (F2=9.52 p=0.05* & F2=5.84 p=0.05*). None 
of the variables were associated with their level of ability to swallow in control 
group. 
Hence there was statistically significant association between the 
effectiveness of apitherapy and selected demographical variables in reducing 
oral mucositis among head and neck cancer patients. 
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CHAPTER-VII 
CONCLUSION AND RECOMMENDATION 
This chapter deals with the conclusions drawn and recommendations. It 
clarifies the limitations of the study. The implications and recommendations 
are given for different areas of nursing such as practice, education, research and 
administration in the health care delivery system. 
7.1. Implications 
The implication had drawn from the present study is a vital concern in 
the field of health team including the professional nurse practitioners, nurse 
administrators, nurse educators and researchers. 
Implications for Nursing Practice 
 The nurses can develop the skill in providing necessary care to head and 
neck cancer patients in reducing oral mucositis by using apitherapy, as it 
help to reduce the degree of oral mucositis among head and neck cancer 
patients undergoing radiation therapy. 
 Apitherapy technique can be practiced in hospital settings as a evidence 
based practice in reducing the degree of oral mucositis among head and 
neck cancer patients undergoing radiation therapy 
 The findings will help the nursing profession to assess the effectiveness of 
apitherapy and could implement the apitherapy technique for head and 
neck cancer patients undergoing radiation therapy. 
Implications for Nursing Education 
 The nurse educator can provide in±service education to nursing personnel 
to update their knowledge about the apitherapy and its benefits to the head 
and neck cancer patients. 
 Nursing students should be educated on apitherapy technique in reducing 
degree oral mucositis among head and neck cancer patients. 
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 The findings will help the student nurses to identify the apitherapy 
technique, and to be motivated in participating to reduce the degree of oral 
mucositis among head and neck cancer patients. 
 The nurse educator can include Apitherapy technique as a means of non±
pharmacological therapy in the curriculum, which can be adopted by the 
students and the nursing personals. 
Implications for Nursing Administration  
 The nurse administrator should conduct in±service education to 
disseminate the research findings through continuous nursing education to 
all nurses. 
 Pamphlets, leaflet about apitherapy technique can be made available to 
nursing staff in the cancer wards and to nurse educators in nursing 
educational institution. 
 Clinical nurses and nurse educators should be given education to update 
their knowledge on apitherapy technique. 
 The findings will help the nurse administrator to take up an important role 
in implementing apitherapy technique in hospital settings. 
Implications for Nursing Research 
 The findings of this study will help to motivate the nurses to conduct 
research about apitherapy technique in future. 
 This study is the foundation to conduct study on larger population to 
strongly prove the efficacy of apitherapy technique on reducing oral 
mucositis among head and neck cancer patients undergoing radiation 
therapy. 
 The findings can be utilized for further research in head and neck cancer 
with oral mucositis. 
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7.2. Limitations 
 The study was confined to small samples in a single setting, which limits 
the study. 
 Data collection period was only four weeks. 
 The study was limited to only 25 to 65 years old subjects. 
 The study was limited to only one hospital. 
7.3. Recommendations for further study 
 A comparative study can also be done between the effectiveness of various 
non ± pharmacological measures on reducing oral mucositis 
 A comparative study can be conducted to evaluate the apitherapy practice 
in various cancer settings. 
 The effect of apitherapy can be assessed in combination with other non 
pharmacological agents and various oral rinses for the good parturient 
outcome. 
 The study can be conducted in a larger population and various age groups. 
 
Conclusion 
From the study conducted it is concluded that honey has good effect on 
oral mucositis in healing. Presence of antibacterial property and antioxidants in 
honey provokes adequate wound healing and also improves immune system. In 
addition to antibacterial activity, honey is known to possess strong antioxidant 
capacity, which acts in modulating free radical production, thus protecting cell 
components from their harmful action. Honey helps in earlier healing of 
wounds and promotes healthy living among cancer patients. Such cost effective 
interventions in hospital practices are highly recommended.  
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APPENDIX-D 
STUDY TOOL (SECTION-A:  DEMOGRAPHIC INFORMATION) 
1. Name of the patient :    
2. Sex  
a. Male Ƒ 
b. Female Ƒ 
 
3. Age in years 
a. 21 to 35 Ƒ 
b. 36 to 50 Ƒ 
c. 51 to 65 Ƒ 
 
4. Religion 
a. Hindu Ƒ 
b. Christian Ƒ 
c. Muslim Ƒ 
d. Others Ƒ 
 
5. Educational qualification  
a. Illiterate Ƒ 
b. Upto Primary level Ƒ 
c. Upto middle school level Ƒ 
d. Higher secondary level Ƒ 
 
6. Total income per month 
a. <5,000  rupees/month Ƒ 
b. 5,001 ± 10,000 rupees/month Ƒ 
c. 10,001 ± 15,000 rupees/month Ƒ 
d. >15,000 rupees/ month Ƒ 
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7. Personal habits 
a. Smoking Ƒ 
b. Alcohol Ƒ 
c. Smoking and alcohol Ƒ 
d. Other tobacco products Ƒ 
e. No habit of tobacco or alcohol abuse Ƒ 
 
8. Family history of cancer 
a. Yes Ƒ 
b. No Ƒ 
c. Not known Ƒ 
 
9. Duration of illness 
a. 0 to 3 months Ƒ 
b. 4 -6 months Ƒ 
c. 7 ± 12 months Ƒ 
d. More than 12 months Ƒ 
 
10. Duration of treatment  
a. 0 -1 months Ƒ 
b. 1 to 6 months Ƒ 
c. More than 6 months   Ƒ 
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SECTION-B National Cancer Institute ± Cancer Toxicity Criteria 
Observational Checklist & Scoring Key 
It consist of 4 items such as 
5. Ulceration 
6. Erythema 
7. Pain 
8. Ability to swallow 
Each item is categorized as follows, 
Ulceration 
 0 = No Lesion Score 0  = No Lesion 
 1 = <1cm2  Score 1-9  = Mild  
 2 = 1-3cm2 Score 10-18  = Moderate 
 3 = >3cm2 Score 19- 27  = Severe 
Erythema 
 0 = No Lesion Score 0  = No Lesion 
 1 = <1cm2 Score 1-9  = Mild  
 2 = 1-3cm2 Score 10-18  = Moderate 
 3 = >3cm2 Score 19- 27  = Severe 
Pain 
 0 = No Pain 
 1-3 = Mild Pain 
 4-6 = Moderate Pain 
 5-9 = Severe Pain 
 10 = Worst Possible Pain 
Ability to swallow 
 Ability to swallow foods without pain    -score 3 
 Ability to swallow with pain    - score 2 
 Requires intravenous rehydration  - score 1 
 Require parenteral or enteral nutrition  - score 0 
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1. ULCERATION   
 
 
 
 
 0 = No Lesion Score 0  = No Lesion 
 1 = <1cm2  Score 1-9  = Mild  
 2 = 1-3cm2 Score 10-18  = Moderate 
 3 = >3cm2 Score 19- 27  = Severe 
 
Inference 
a) No lesion 
b) Mild 
c) Moderate 
d) Severe 
  
 
 
LOCATION ULCERATION 
UPPER LIP 0 1 2 3 
LOWER LIP 0 1 2 3 
LEFT CHEEK 0 1 2 3 
RIGHT VENTRAL AND LATERAL TONGUE 0 1 2 3 
LEFT VENTRAL AND LATERAL TONGUE 0 1 2 3 
FLOOR OF THE MOUTH 0 1 2 3 
SOFT PALATE / FAUCES 0 1 2 3 
HARD PALATE 0 1 2 3 
Sub Total     
Total     
  x  
 
 
2. ERYTHEMA 
 
 
 0 = No Lesion Score 0  = No Lesion 
 1 = <1cm2  Score 1-9  = Mild  
 2 = 1-3cm2 Score 10-18  = Moderate 
 3 = >3cm2 Score 19- 27  = Severe 
 
Inference 
a) No lesion 
b) Mild 
c) Moderate 
d) Severe 
 
 
 
LOCATION ULCERATION 
UPPER LIP 0 1 2 3 
LOWER LIP 0 1 2 3 
LEFT CHEEK 0 1 2 3 
RIGHT VENTRAL AND LATERAL TONGUE 0 1 2 3 
LEFT VENTRAL AND LATERAL TONGUE 0 1 2 3 
FLOOR OF THE MOUTH 0 1 2 3 
SOFT PALATE / FAUCES 0 1 2 3 
HARD PALATE 0 1 2 3 
Sub Total     
Total     
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3. PAIN 
No 
pain Mild Moderate severe 
Worst 
pain 
0 1 2 3 4 5 6 7 8 9 10 
 
a) 0 = no pain Score 0 
b) 1-3 = mild pain Score 1 
c) 4-6 = moderate pain Score 2 
d) 7-9 = severe pain Score 3 
e) 10 = worst possible pain Score 4 
 
4. ABILITY TO SWALLOW 
 
a) Able to swallow foods without pain    -score 3 
b) Able to swallow with pain    - score 2 
c) Requires intravenous rehydration  - score 1 
d) Require parenteral or enteral nutrition  - score 0 
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APITHERAPY PROCEDURE 
DEFINITION:  
Apitherapy or bee therapy is the use of products of the common honey 
bee for therapeutic purposes.  
PURPOSE:  
 To promote healing.  
 To reduce the level of pain.  
 7RLPSURYHERG\¶VLPPXQHV\VWHP 
PREPARTION OF THE PATIENT:  
 Explain the procedure to the patient.  
ARTICLES:  
 Honey   
 Ounce glass  
PROCEDURE: 
 Explain procedure to the subjects. 
 Obtain consent from the subjects. 
 Make the subject comfortable position. 
 Ask the subject to swish with water. 
 Pre assessment of oral mucositis. 
 Apitherapy (20ml) of honey orally given to the patients before 15minutes 
and after 15 minutes of radiation therapy, ask the patient to swish 20 ml of 
honey for 5 minutes then swallow it. 
 Do the procedure gently. 
 Repeat the procedure until end of 3rd phase. 
 Post assessment of oral mucositis. 
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HONEY RELATED INFORMATION 
INTRODUCTION 
+RQH\ LV RQH RI QDWXUH¶VZRQGHU LW LV QHFWDU JDWKHUHG IURP WKH EORVVRPV RI
many flowers by bees. It is then taken in to the beehive and changed by the 
worker bees. Worker bees remove the liquid from the nectar. The finished 
product is heavy syrup with 12 to 20 percent moisture and 80 to 85 percent 
sugar. It is a good source of quick energy for the human body. 
DEFINITION 
The definition of honey stipulates a pure product that does not allow for the 
addition of any other substance. This includes water or other sweeteners. 
THE CONTENTS OF HONEY 
 Sugar like fructose, glucose, sucrose, maltose, lactose and other 
disaccharides and trisaccharides 
 Proteins, fats, vitamins, minerals, enzymes and amino acids 
 Volatile aromatic substances 
 Ashes and water etc 
THE HONEY ANALYSIS 
)UXFWRVH 
*OXFRVH 
6XFURVH 
0DOWRVH 
:DWHU 
+LJKHUVXJDU 
$VK 
2WKHUXQGHWHUPLQHG 
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NURTITIONAL VALUE PER 100g (3.5oZ) 
 Energy : 1,272 KJ (304 K cal) 
 Carbohydrate : 82.4 g 
 Sugars : 82.12 g 
 Dietary fiber : 0.2 g 
 Fat : 0 g 
 Protein : 0.3 g 
 Water : 17.10 g 
 Riboflavin (vit.B2) : 0.038 mg (3%) 
 Niacin (vit.B3) : 0.121 mg (1%) 
 Pantothenic acid (B5) : 0.068 mg (1%) 
 Vitamin B6 : 0.024 mg (2%) 
 Vitamin C : 0.5 mg (1%) 
 Calcium : 6 mg (1%) 
 Iron : 0.42 mg (3%) 
 Magnesium : 2 mg (1%) 
 Phosphorus : 4 mg (1%) 
 Potassium : 52 mg (1%) 
 Sodium : 4 mg (0%) 
 Zinc : 0.22 mg (2%) 
BENEFITS OF HONEY 
 The most common use of honey as a microbial agent it as a dressing for 
wounds, burns and skin ulcers. This application has a long history in 
traditional medicine, additionally the use of honey reduces odors, reduces 
swelling, and reduces scarring, it also prevents the dressing from sticking 
to the healing wound. 
 The honey has antibacterial properties has been established for over a 
century, but in many cultures it has been used as a medicine. It is now less 
established that honey inhibits a broad spectrum of bacterial and fungal 
species. 
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 Honey has powerful antimicrobial properties, which can soothe your raw 
tissue. Pour a teaspoon of honey into a large serving spoon and then top 
off the spoon with lemon juice. Swallow the concoction (without water) 
every few hours until symptoms clear up. Some people add a pinch of 
black or red pepper to increase blood circulation to the throat 
 Honey is useful for the skin diseases. It can be applied externally for 
wounds, sores and burns. It is also believed to minizing disfiguring scar. 
 Honey is useful in providing energy to the body. 
 As it contains sugars which are quickly absorbed by the digestive system 
and converted in to energy. This can be used as instant energizer. 
 As it is hygroscopic, it speeds up healing tissue and dries it up. 
 Honey act as a sedative and it very useful in bed wetting disorders. 
 Honey is very good antioxidant which restores the damaged skin and 
gives soft, young looks. 
 Honey has antibacterial properties due to its acidic nature and 
enzymatically produced hydrogen peroxide. 
 Constant use of honey strengthens the white blood corpuscles to fight 
bacterial and viral diseases. 
PRECAUTIONS TO BE TAKEN BEFORE USING HONEY 
 Honey should not be mixed with hot foods 
 Honey should not be heated 
 Honey should not be consumed when working in hot environment where 
you are exposed to more heat 
 Honey should never be mixed with rain water, hot and spicy foods, and 
fermented beverages like whisky, rum, brandy, ghee and mustard. 
 Honey includes nectar of various flowers of which some may be 
poisonous. Poison has hot or Ushant qualities. When honey is mixed 
with hot and spicy foods the poisonous properties get enhanced and 
cause imbalance of health status. 
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APPENDIX - E
INFORMED CONSENT 
Title of the study   : ³A study to assess the effectiveness of apitherapy in 
reducing oral mucositis among head and neck cancer patients 
undergoing radiation therapy at Rajiv Gandhi Government General 
+RVSLWDO&KHQQDL´ 
Investigator           : Sonia.M 
Name of Participant    : 
Age/sex          : 
Date            : 
Name of the institution : Rajiv Gandhi Government General Hospital, 
Chennai-3 
x I               have read/it has been read for me, the 
information      in this form. I was free to ask any questions and they have 
been answered. I am over 20 yrs of age and exercising my free power of 
choice, hereby give my consent to be included as a participant in the study. 
x I have read and understood this consent form and the information provided 
to me. 
x I have had the consent document explained in detail to me & been 
explained about the nature of my study. 
x My rights and responsibilities have been explained to me by the 
investigator. 
x I agree to cooperate with the investigator & I have not participated in any 
research study at any time. 
x I am aware of the fact that I can opt out of the study at any time without 
having to give any reason  
x I hereby give permission to the investigators to release the information 
obtained from me as a result of participation in this study to the regulatory 
authorities, government agencies and Institutional ethics committee. 
x  I understand that they are publically presented; my identity will be kept 
confidential. 
x I am aware that I have any question during this study; I should contact the 
concerned investigator. 
 
Signature of Investigator               Signature of Participant    
Date:         Date: 
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INFORMATION TO PARTICIPANTS 
Title of the study: ³A study to assess the effectiveness of apitherapy in   
reducing oral mucositis among head and neck cancer patients 
undergoing radiation therapy at Rajiv Gandhi Government General 
Hospital, Chennai.´ 
Name of the Participant :    Age/sex : 
Date    :   
Investigator   : Sonia.M 
Name of the institution : Rajiv Gandhi Government General Hospital, 
Chennai-3 
Enrollment  No  : 
You are invited to take part in this study. The information in this 
document is meant to help you decide whether or not to take part. Please feel 
free to ask if you have any queries or concerns. You are being asked to co-
operate in this study being conducted in Rajiv Gandhi Government General 
Hospital, Chennai-3. 
What is the Purpose of the Research (explain briefly) 
 This research is conducted to evaluate the effectiveness of Apitherapy 
among head and neck cancer patients undergoing radiation therapy in Rajiv 
Gandhi Government General Hospital, Chennai-3. We have obtained 
permission from the Institutional Ethics Committee. 
Study Procedure 
 The study will be conducted after obtaining approval from Institutional 
Ethics Committee. 
 Patients with head and neck cancer on radiation therapy will be explained 
about the study procedures and purpose. 
 Informed consent will be obtained from those who are willing to 
participate. 
 Those who fulfill the inclusion criteria will be enrolled and randomized to 
either experimental or control group. 
 Pre test assessment of oral mucosa will be done by National Cancer 
Institute ± Cancer Toxicity Criteria (NCI-CTC) scale for both groups. 
 The experimental group will receive oral application of apitherapy before 
radiation therapy, 15mins and 6 hrs after radiation therapy for 3 cycles. At 
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the end of 3 cycles the oral mucosa will be evaluated for mucositis by 
National Cancer Institute ± Cancer Toxicity Criteria (NCI-CTC) scale.   
 The control group will undergo oral mucosa examination for 3 cycles.    
Possible Risks to you 
 No risks involved. 
Possible Benefits to you 
 After finishing this study, investigator will provide information that 
apitherapy is effective in reducing oral mucositis among head and neck cancer 
patients undergoing radiation therapy. 
Possible benefits to other people 
          The result of the research may provide benefits to the head and neck 
cancer patients and also empathetic care to them by investigator. 
Confidentiality of the information obtained from you 
         You have the right to confidentiality regarding the privacy of your 
personal details. Your privacy in the study will be maintained throughout the 
study in the event of any publication or presentation resulting from the 
research, no personally identifiable information will be shared. The information 
from this study, if published in scientific journals or presented at scientific 
meetings, will not reveal your identity. 
How will your decision not to participate in the study affect you? 
         Your decisions not to participate in this research study will not affect 
your activity of daily living, medical care or your relationship with investigator 
or the institution. 
Can you decide to stop participating in the study once you start? 
         The participation in this research is purely voluntary and you have the 
right to withdraw from this study at any time during course of the study without 
giving any reasons. 
However, it is advisable that you talk to the research team prior to 
stopping the treatment. 
 
Signature of Investigator  Signature of Participant 
Date:        Date:
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CODING SHEET ± EXPERIMENTAL GROUP
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1 a b a c b c b d a c b c b c b b b 
2 b b a b b e b b b c b c b d b b a 
3 a b a b b e b a b c b c b c b b a 
4 a c a b b c b a a c b c b d b b a 
5 a c a a a c b b a d b d b d b d b 
6 a b a a a c b a a c b c b d b c a 
7 a c a b a c b a a c b c b c a b a 
8 a a a b a d b a a d b d b d b c b 
9 a b a b b c b b b c b c b c a b a 
10 a b a c c c b a a c b b b b a b a 
11 b a a b b e b a a c b b b b a b a 
12 b b a a a e b b b d b d b d b c b 
13 a b a c b d b a a c b c b c a b a 
14 b c a a a e b a a c b c b c a b a 
15 a c a b b c b a a c b c b c b a a 
16 a c a a a a b a a c b b a b a b a 
17 a b b d c c b b a c b c b b a b a 
18 b b b b b b b a a c b c b c b b a 
19 a c b b b c b a a c b c b b a b a 
20 a c a b b c b a a c b c b c a b a 
21 a c a b a d b a a c b c b c b b a 
22 a c a a b c b a a c b c b b a a a 
23 a c a b b d b a a c b c b c b b a 
24 a a a b b a b a a c b c b b a b a 
25 a c a c b c b a a b b b a b a a a 
26 a b a b b a b a a b b b b b a a a 
27 a c a b b c b a a a a a a a a a a 
28 a c a b b c b a a b a b a b a a a 
29 a c a c b c b a a b a b a b a a a 
30 a b a c b c b a a b b b b b a a a 
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CODING SHEET ± CONTROL GROUP 
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4 a b c b a d c b a b c b c c c b b 
5 a b b d c c b a a c c c c c c b b 
6 a c a b a c b b a b c b c c b a b 
7 a b a b b d b a a b c b c b c a b 
8 a b a b a c b b a c c c c c b b b 
9 a b a b a c b a a c c c c b c a b 
10 b b a b a e b a a c c c c b c a b 
11 a b a a a c c a a c c c c c b a b 
12 a a a b a c b a a b c b c a b a b 
13 a c a b a d b a a a b a b a b a b 
14 a c a a a a b b b b c b c a b a b 
15 a b a b a a b b b b c b c a b a b 
16 a a b b b e b a a b c b c a b a b 
17 b b c b b d b a a b c b c a b a b 
18 a b a b b b b a a b c b c a b a b 
19 a c a b b c b a a b c b c a b a b 
20 a b a b b c b b b b c b c a b a b 
21 a b a b a a b a a b b b b a b a b 
22 a c a b b d a a a b b b c a b a b 
23 b c a b b a b a a b b b b b b a b 
24 b c a a a e b a a b b b c b b a b 
25 b c a a a e b a a c c c c b b a b 
26 a c a a a a b a a c c c c b b a b 
27 a c a b b c b a a c c c c b c a b 
28 a a a c b c b b b c c c c b c a b 
29 a b b c b b b a a c c c c b c a b 
30 b c a a a e b a a c c b c b c a b 
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